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VITAMIN D, TISSUE RESISTANCE, BONE MINERAL DENSITY AND 
 BREAST CANCER RISK 
 
Jessica D. Albano, PhD 
University of Pittsburgh, 2009 
Etiologic factors such as vitamin D and estrogen are potentially related to breast cancer 
development, although details of their mechanisms are not completely understood. We 
prospectively investigated correlates of breast cancer risk among postmenopausal women in 
the Study of Osteoporotic Fractures (SOF). First, we undertook a case-cohort study to test the 
hypothesis that low serum 25-hydroxyvitamin D [25(OH)D] will be associated with an increased 
risk of ER+ breast cancer (N=502). Low 25(OH)D levels were not associated with an increased 
risk of breast cancer and do not support an association between 25(OH)D and ER+ breast 
cancer development. Second, we utilized fractional calcium absorption (FCA) as a marker of 
tissue resistance to vitamin D to test the hypothesis that low FCA will be associated with an 
increased risk of breast cancer (N=5035). To the contrary, over a mean 9.6 years, increasing 
rates of FCA were associated with a higher risk of invasive breast cancer. A stronger positive 
relationship was noted among women with low dietary calcium intake. The findings support a 
modestly increased risk of breast cancer with higher FCA rates particularly among those who 
have low calcium intake. Finally, we examined the long-term association of an initial bone 
mineral density (BMD) measure and change in BMD (annual percent change assessed 3.5 
years later) on breast cancer risk (N=5385). Furthermore, we tested the hypothesis that the risk 
associated with an initial BMD measure would be strengthened by the addition of the change 
variable. Over a mean 9.5 years, there was no association between increasing levels of BMD, 
change in BMD, or a combined model and breast cancer. The effect of BMD was found to be 
dependent upon family history of breast cancer. Among women with a positive family history, 
high BMD was associated with a 3-fold higher risk of breast cancer compared to low BMD. 
Through our investigations of two etiologic factors and their association with breast cancer 
development, we have enhanced our knowledge regarding the interdependence of vitamin D, 
calcium, and estrogen. These findings may lead to improved opportunities for prevention and 
early detection and are of significant public health relevance. 
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 1.0  INTRODUCTION 
Breast cancer is the most commonly diagnosed cancer, and the second leading cause of cancer 
mortality among women in the United States. Although the rising incidence has recently waned, 
our ability to assess a woman’s risk of developing breast cancer and implement preventive 
measures is limited. The focus of this dissertation is on two potentially etiologic factors for 
breast cancer.  
First, the association of vitamin D in tumor development was investigated. In addition to 
its role in building bone, vitamin D has a separate function in cancer prevention. Specifically, 
1,25-dihydroxyvitamin D [1,25(OH)2D], the biologically active form of vitamin D, is responsible 
for genetic regulation of cellular processes such as controlling proliferation, inhibiting 
angiogenesis, and inducing differentiation and apoptosis. These actions are carried out locally in 
tissues containing the vitamin D receptor (VDR) such as the breast where circulating 25-
hydroxyvitamin D [25(OH)D] is converted to 1,25(OH)2D. Therefore, the serum concentration of 
25(OH)D may be a predictor of breast cancer risk. There is the potential, however, for tissue to 
lose its sensitivity to 1,25(OH)2D with age. This is demonstrated in the gut where fractional 
calcium absorption (FCA), a measure of the rate of calcium uptake, is maintained despite 
increased levels of 1,25(OH)2D. It is not known whether other tissues might also develop 
resistance to 1,25(OH)2D over time. FCA could potentially be used as an indicator of tissue 
sensitivity to 1,25(OH)2D beyond the small intestine and help to clarify the role of vitamin D in 
breast cancer development.  
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 Second, we investigate estrogen. Estrogen plays an important role in the development of 
breast cancer. Estrogen, along with growth factors, vitamin D, parathyroid hormone (PTH), and 
calcium are important factors contributing to bone health. Bone mineral density (BMD), a 
measure of bone strength, is hypothesized to be a surrogate marker for cumulative estrogen 
exposure because bone contains estrogen receptors making it sensitive to levels of circulating 
estrogens. BMD may predict future breast cancer occurrence.  
In light of the number of women affected with breast cancer, it becomes increasingly 
important to understand this disease and to identify potentially modifiable risk factors along with 
the women who might benefit from targeted prevention strategies. Established risk factors 
explain little of the variability in breast cancer and therefore there is a need to identify additional 
risk factors. This becomes an increasingly difficult task given the heterogeneity of breast cancer 
risk factors that exists between premenopausal and postmenopausal women, as well as the 
differences in pathologic features of breast tumors in older women. The following literature 
review presents a brief overview of the epidemiology of breast cancer and known risk factors. A 
more detailed background on vitamin D, fractional calcium absorption, and bone mineral 
density, as they relate to breast cancer is also provided. 
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 2.0  LITERATURE REVIEW 
2.1 EPIDEMIOLOGY OF BREAST CANCER 
2.1.1 Incidence, Survival and Mortality 
Breast cancer is the most commonly diagnosed cancer, and the second leading cause of cancer 
mortality among women in the United States. The incidence of breast cancer from 2000 to 2004 
in the US was 125.3/100,000 and the mortality rate was 25.5/100,000.1, 2  The number of 
women affected by breast cancer annually is not insignificant, with a projected 182,460 new 
cases of invasive breast cancer and 40,480 deaths expected to occur in the United States in 
2008.2  After increasing for several decades, female breast cancer incidence rates decreased 
between 2001 and 2004.2  Two distinct patterns in recent breast cancer trends have emerged. 
The subtle downturn in incidence rates for all women over age 45 is reflective of the saturation 
of screening mammography utilization, where as the sharp decrease in incidences among 
women aged 50 to 69 years is more likely to be attributed to the reduction in the use of hormone 
therapies (HT), as tumors in women this age are predominantly estrogen receptor positive 
(ER+) and hence sensitive to levels of circulating hormones.3  Overall, mortality due to breast 
cancer has been steadily declining since the early 1990’s.2  The 5-year relative survival from 
breast cancer is 89%, but varies greatly depending upon stage at diagnosis with a range of 98% 
for localized tumors to 27% for metastatic disease.2  Survival is greatest for women diagnosed 
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 at age 40 or older with a 5-year survival of 89% compared to 82% for those under age 40.4  
Long-term survival is greater among individuals with a ER+ tumor and a stronger degree of 
positivity for tamoxifen therapy. In quantitative terms, women with estrogen receptor negative 
(ER-) tumors have an 8% to 35% lower 5-year survival rate compared to those with ER+ 
tumors.5  
2.1.2 Age 
The majority of breast cancer cases occur among women over age 50, with a peak in incidence 
at 75-79 years of age.6  Women over the age of 50 have an incidence rate of 375 / 100,000 
compared to 42.5 / 100,000 among women less than 50 years of age.6  For women, the lifetime 
probability of developing invasive breast cancer is 1 in 8; age specific probabilities are 1 in 26 
(40-59 years), 1 in 28 (60-69 years), and 1 in 15 for those over age 70.2  The proportion of 
women diagnosed with distant-stage disease increases with age,7 as does the proportion of 
tumors expressing hormone receptors.5, 8  Figure 1 shows the age-specific invasive breast 
cancer incidence rates overall and by estrogen receptor status. Approximately 75% of breast 
cancers in older women are ER+. Such pathologic differences may reflect unique biologic 
influences on breast cancer occurrence in older women.9 
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Figure 1. Age-specific invasive breast cancer incidence rates, 2004-2005 
National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) 
2.1.3 Race and Ethnicity 
Breast cancer is the most common cancer among women of every major ethnic group. 
However, there are differences by race.  Age-adjusted incidence rates are highest among white 
women (133/100,000) and lower among black women (118/100,000), Asian American and 
Pacific Islanders (89/100,000), Hispanic/Latinas (89/100,000), and America Indian and Alaskan 
Natives (70/100,000) for the time period of 2000-2004.2  The distribution of age at onset differs 
by race; black women have earlier age at onset with less frequent postmenopausal breast 
cancer occurrence. With the exception of black women, differences in incidence rates among 
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 racial and ethnic groups were shown to be explained by differences in other risk factors.10  
There are also differences in survival and mortality among racial groups. The death rate is 36% 
higher in black women compared to white women in the United States, and the relative 5-year 
survival is 77% and 90% for black and white women respectively.2   
2.2 RISK FACTORS FOR POSTMENOPAUSAL BREAST CANCER 
2.2.1 Reproductive Aspects 
Reproductive factors influencing the risk of breast cancer include age at menarche, age at first 
live birth, age at menopause, parity, and breastfeeding, as these factors are key determinants of 
hormone exposure. Prolonged exposure and higher concentrations of endogenous estrogen 
increases the risk of breast cancer in postmenopausal women.11  Estrogen production is 
controlled by ovarian function, however, after menopause, the main sources of estrogen are 
from peripheral conversion of androtestosterone, an adrenal hormone, to estrone which 
primarily occurs in fat tissue.12  Older age at menarche13 and younger age at menopause11, 13, 14 
are both associated with a lower risk of breast cancer possibly due to a decreased lifetime 
exposure to hormones. Indeed, induced menopause through surgical means (i.e. bilateral 
oophorectomy) decreases the risk of breast cancer.15 
Parous women have a decreased risk of breast cancer compared to nulliparous 
women,11, 13, 16, 17 and the younger a woman is at her first full-term pregnancy, the lower her risk 
of breast cancer.11, 13, 17  The Nurses’ Health Study showed a 20% decreased risk of breast 
cancer in parous versus nulliparous women with a first birth at age 20.17  The benefit is reduced 
to 10% with a first birth is at age 25. The risk however for a first birth at age 35 is actually 
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 greater than that of nulliparous women. The protection associated with parity, is proposed to be 
due to pregnancy induced cellular differentiation of breast tissue which guards against 
exposures to cancer initiating events. The extent of the protective effect is greater at younger 
ages of first birth as the tissue maturation process is completed earlier in a woman’s lifespan.18 
The greater the number of subsequent live births incrementally decreases the risk of breast 
cancer, there is however a short-term increased risk of breast cancer following each 
pregnancy.16 
Breastfeeding is weakly protective against breast cancer depending on both the duration 
(4.3% per 12 months) and number of births (7% per child).19, 20  Prolonged lactation offers a 
small amount of decreased risk, although this may be limited to premenopausal breast cancer, 
likely due to the inhibitory effect of breastfeeding on ovulation and reduced estrogen 
production.21 
2.2.2 Hormonal Factors 
Sex hormones play a central role in the etiology of breast cancer as evidenced by the rapid 
increase in breast cancer rates in the premenopausal years followed by a sudden slowing in the 
increasing rates at menopause when endogenous hormone levels decline rapidly. Among 
postmenopausal women, there is a clear increased risk of breast cancer with increasing levels 
of circulating endogenous hormones, including estradiol and testosterone.22-28  Results are even 
stronger for ER+ breast cancers.26  Studies of the relationship in premenopausal women have 
found conflicting results,28-32 and again, differences are seen by estrogen receptor status.29, 32  
Exogenous hormone exposures are typically through oral contraceptives among 
premenopausal women and hormone therapy (HT) among postmenopausal women. Little to no 
increased risk of breast cancer is associated with oral contraceptive use.33, 34  Conversely, HT is 
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 related to an increased risk of breast cancer. As demonstrated in the randomized controlled trial 
of the Women’s Health Initiative (WHI), combined estrogen plus progesterone is clearly related 
to an increase in the risk of breast cancer.35, 36  Risk is greater for ER+ cancers,37 and with 
longer duration of use.23, 25  As recently reviewed by Santen et al., the evidence is less clear 
concerning hormone therapies where estrogen is unopposed, typically prescribed for women 
who have undergone a hysterectomy.38  The estrogen-alone arm of the WHI randomized trial 
found no association.39  Other studies have found no association,39, 40 a decreased risk,41-43 or 
an increased risk.41, 44, 45    
2.2.3 Anthropometry 
Obesity is positively related to postmenopausal breast cancer, however, there is an opposite, 
inverse association among premenopausal women.  The higher levels of circulating estrogens 
found in heavier women have been attributed to the greater amount of adipose tissue.46, 47 In 
postmenopausal women, adipose tissue is the major source of estrogen, and obese 
postmenopausal women have both higher levels of endogenous estrogen and a higher risk of 
breast cancer.48, 49  Among postmenopausal women, higher body mass index (BMI) posed a 
greater risk of breast cancer (RR 1.3 for ≥ 25 vs. < 21 kg/m2, 95%CI 1.1-1.5).50  In addition, the 
increased risk among heavier women appears to be greater for never users of HT.51, 52  A study 
of women enrolled in the WHI who never used HT found increased BMI to be a strong predictor 
of breast cancer risk among younger postmenopausal women (50-59 years) but not associated 
among older women (70-79 years).51  This is in contrast to an earlier study reporting a greater 
risk among older postmenopausal women.50  Being obese (BMI ≥ 30 kg/m2) is also associated 
with an increased risk of dying from breast cancer.53  Recently, the effect of BMI on breast 
cancer mortality was shown to be age dependent with an increased risk of death with higher 
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 BMI at age 65 yet a decreased risk of death with higher BMI at age 85.54 The relationship 
among premenopausal women on the other hand, is contradictory; high BMI (> 31 kg/m2) is 
protective against breast cancer compared to low BMI (< 21 kg/m2).50  The reduction in breast 
cancer risk among obese premenopausal women may be due in part to suppressed ovulation.55  
Height is positively associated with breast cancer risk. Taller women (≥ 175 cm) have 
been found to be 20% more likely to develop breast cancer than shorter women (< 160 cm).50  
Higher levels of dense breast tissue are associated with increased breast cancer risk.56, 
57   Several factors suggest that the relationship maybe independent of estrogen. Firstly, 
mammographic density is largely an inherited trait,58 secondly, ER+ and ER- tumors are equally 
represented,59 and thirdly, breast density measures have not been found to correlate highly with 
sex hormone levels.60 
2.2.4 Family History / Genetics 
Family history is an important risk factor for breast cancer despite the fact that only 15-20% of 
women with breast cancer report a positive family history. Risk of breast cancer increases with a 
greater number of affected first degree relatives.61  Specific genes such as BRCAI/II, p53, and 
AT convey an increased risk of breast cancer. While the risk to individuals with such a mutation 
is high (approximately 90% for BRCA), the prevalence is low and hence they account for only 
about 5% of breast cancer cases in the general population. 
2.2.5 Benign Breast Disease 
Of the major histologic categories of benign breast disease, atypical hyperplasia, proliferative 
lesions, are most highly associated with increased breast cancer risk (RR 3.9, 95%CI 2.6-5.9) 
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 as observed in the Nurses’ Health Study.62  The risk, however, appears to be greater among 
premenopausal (RR 5.3, 95%CI 2.6-10.7) compared to postmenopausal women (RR 3.7, 
95%CI 2.1-6.6).  
2.2.6 Lifestyle 
Physical activity is modestly protective against developing breast cancer, with an estimated 
average risk reduction of 30 to 40%.63-66  This evidence is more consistent for postmenopausal 
women.63, 67-69  The Women’s Health Initiative reported a reduced risk of 37% for normal weight 
women engaging in at least 10 hours of brisk walking per week.68  This may be mediated 
through weight control, or the associated reduction in circulating estrogen concentrations with 
increasing levels of physical activity.47, 70 
Alcohol consumption has been consistently associated with an increased risk of breast 
cancer. Compared with nondrinkers, daily alcohol consumption has been associated with as 
much as a 40% increased risk (RR 1.41 for 2+ drinks/day, 95%CI 1.18-1.69) by a pooled 
analysis of 6 cohort studies,71 and as little as a 6% increased risk (RR 1.06 for 1 drink/day, 
95%CI 1.00-1.11) by a meta-analysis of 5 cohort studies.72  No differences were noted by 
menopausal status.72  The effect is more pronounced for ER+ breast cancer73-75 and when 
combined with HT.73, 74, 76  The combination of 1.5 to 2 drinks daily with current HT use for at 
least five years was associated with a doubling of the risk of breast cancer compared to 
nondrinking, nonusers of HT (RR 1.99, 95%CI 1.42-2.79).76  
The relationship between smoking and breast cancer risk is complex due to interactions 
with other risk factors including alcohol, obesity, and endogenous hormones.77, 78   Despite this, 
most studies have shown a modestly increased risk of breast cancer with smoking (RR 1.17, 
95%CI 1.02-1.34).79  In addition, the risk may differ my menopausal status with a protective 
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 effect among postmenopausal women (OR 0.5, 95%CI 0.3-0.9) who experienced increasing 
BMI throughout life and initiated smoking later.78 
2.2.7 Risk Factors among Older Women  
Reports of differences in traditional breast cancer risk factors by both menopausal status and 
older age continue to mount. A study of women 75 years and older, found women with a high 
BMI (HR 1.44 for > 29.5 vs. < 23.5 kg/m2, 95%CI 1.12-1.84), a family history of breast cancer in 
a first degree relative (HR 1.54, 95%CI 1.24-1.93), and an older age at menopause (ptrend=0.07) 
to have an increased risk of breast cancer, while having had five or more children compared to 
one or two was protective (HR 0.67, 95%CI 0.51-0.88).9  Traditional breast cancer risk factors 
not associated with increased risk among the those over 75 years were nulliparity, age at first 
live birth, and age at menarche. A pooled analysis of reproductive risk factors by age at 
diagnosis (premenopausal or < 50 years vs. post-menopausal or > 50 years) found that while 
breast cancer risk decreased with increasing age at menarche for both groups, the decreased 
risk was approximately 9%  per year of later menses onset for the younger women compared to 
4% per year among the older women.80  Similar results were found for age at first birth; risk of 
breast cancer increased 5% per year vs. 3% per year for younger vs. older women. In contrast, 
the risk of breast cancer was decreased by 12% for each live birth among the older women, but 
only 3% among the younger women.81  It has been suggested that risk factors representing 
hormonal exposures of the distant past, will show attenuated risk ratios with rising breast cancer 
incidence with age, where as more recent indicators remain relevant to the risk of breast cancer 
among the elderly.9 
11 
 
 2.2.8 Risk Factors by Estrogen Receptor Status 
Breast cancer risk factors vary by hormone receptor status. The protective effects of 
reproductive risk factors such as delayed menarche,82 higher parity,82-85 younger age at first 
birth,82-86 and early menopause82, 85 tend to be stronger for ER+ breast cancer. However such 
findings are not entirely consistent as others have reported similar risks for ER+ and ER- tumors 
for older age at menarche,84, 85 and parity.86, 87  A meta-analysis by Ma et al. reported an 11% 
reduction in ER+/PR+ breast cancer risk with each additional birth and a 27% increased risk for 
women in the oldest versus the youngest category of age at first birth.84  
Other breast cancer risk factors that show a greater association with ER+ breast cancer 
include height,88 hormone use,37, 86, 88 body mass index,82, 85, 86, 89 physical activity,67 and  alcohol 
intake.73-75  The Women’s Health Study reported a modest relative risk per 1 drink/day of alcohol 
intake of 1.11 (95%CI 1.03-1.20) for ER+/PR+ tumors, 1.00 (95%CI 0.81-1.24) for ER+/PR- 
tumors, and 0.99 (95%CI 0.82-1.20) for ER-/PR- tumors.74  Similar results were reported by a 
case-control study among a group of women aged 65-79 years who had ever used alcohol.75 
The Swedish Mammography Cohort however, reports an elevated risk of postmenopausal 
breast cancer with ≥ 1 drink/day versus none for both ER+/PR+ (RR 1.35, 95%CI 1.02-1.80) 
and ER+/PR- (RR 2.36, 95%CI 1.56-3.56) but not ER- subtypes.73 
Family history, on the other hand, is one breast cancer risk factor found to be more 
strongly related to ER- breast cancer.82 
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 2.2.9 Summary of Risk Factors 
Table 1. Summary of breast cancer risk factors by menopausal status 
Risk Factor Premenopausal Postmenopausal 
Family history of breast cancer +++ +++ 
Benign breast disease ++++ ++++ 
Late age at menarche + + 
Late age at menopause n/a ++ 
Late age at first birth + + 
Higher parity -- -- 
Breastfeeding -- -- 
Exogenous hormone use + ++ 
Height ++ ++ 
Weight -- ++ 
Obesity -- ++ 
Physical activity -- -- 
Alcohol + + 
Smoking ++ + 
Scale: RR < 1.0, --; 1.0-1.25, +; 1.25-1.50, ++; 1.50-2.00, +++; > 2.00, ++++ 
2.3 HORMONE RECEPTOR STATUS DETERMINATION  
13 
Breast cancer is dependent upon estrogen or progesterone for growth. The stimulatory effect is 
mediated through estrogen receptors (ERα and ERβ) and progesterone receptors (PRa and 
PRb), which are over-expressed in most breast tumors.90  Estrogen receptors belong to a 
superfamily of nuclear hormone receptors, including other steroid hormone receptors such as 
vitamin D (VDR), that function as transcription factors when they are bound to their respective 
ligands.90  The majority of breast tumors co-express ERα and ERβ. A study of ER expression 
found 62% of breast tumors to be ERα+/ERβ+, 14% ERα+/ERβ-, 15% ERα-/ERβ+, and 9% ERα-
/ERβ-.91  
 
 ER and PR detection and quantification is done by either dextran-coated charcoal 
(DCC), which utilizes competitive binding of radiolabeled steroid ligand, or 
immunohistochemistry (IHC) and enzyme immunoassay (EIA) which are based on recognition 
of the receptor protein by specific antibodies.92  The two ER subtypes (α and β) have similar 
estrogen binding affinity, however, ERα is the predominant isoform used to determine ER status. 
Although ER status is often considered to be a dichotomous factor, i.e. positive or negative, ER 
concentration is actually measured on a continuous scale from 0 to 1,000 femtomoles per 
milligram (fmol/mg) with a positive range between 3 and 20 fmol/mg.92  
While DCC is highly reproducible, variation is greatest between 3 and 10 fmol/mg and 
therefore 10 fmol/mg is the typical cutpoint used to determine ER+ status.92  DCC is also known 
to give false-negative results in instances of high levels of circulating hormones such as 
estrogens due to receptor site saturation unlike IHC which is not affected by steroid hormone 
levels.92  IHC’s simplicity and relatively low cost make it the predominant method utilized in 
clinical practice. One drawback to IHC is that, unlike EIA it is not objectively quantitative. Recent 
studies have reported a bimodal ER status with 90% of tumors being either completely negative 
or very strongly positive with the IHC technology.93  Despite this, comparative studies have 
reported high correlations in ER status reporting for DCC to IHC (80-90%), EIA to DCC (80%), 
and  EIA to IHC (90%).92  
In many observational studies, ER status is mainly determined through review of patient 
medical records. A recent comparison of ER status abstracted from pathology reports (where 
ER status was determined from many different labs, over a long period of time, and by several 
different methods) to corresponding measures by a single method (IHC) at a central laboratory 
found agreement for 87% of specimens (kappa=0.64, p<0.01), indicating that pathology reports 
are a reliable source for determining ER status.94  In addition, the rate of tumors with 
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 unspecified ER/PR status has decreased from more than 80/100,000 cases in 1990 to 
approximately 40/100,000 cases in 2003.3   
2.4 VITAMIN D AND BREAST CANCER RISK  
2.4.1 Biologic Plausibility 
Vitamin D is available through exposure to sunlight, supplements, and dietary intake. Vitamin D 
produced in the skin and consumed in fortified foods (vitamin D3, cholecalciferol, technically a 
prosteroid hormone) or consumed in the form of plant sterols (vitamin D2, ergocalciferol) is 
biologically inert and must undergo two enzymatic hydroxylations to become biologically 
active.95  Figure 2 details the synthesis and metabolism of vitamin D. Following absorption, 
vitamin D is first metabolized by the liver into its principal circulating metabolites, 25-
hydroxyvitamin D3 [25(OH)D3], and 25-hydroxyvitamin D2 [25(OH)D2]. 25(OH)D refers to both 
25(OH)D2 and 25(OH)D3 and will be used throughout the text. Because liver production of 
25(OH)D is not highly regulated, measured levels of these metabolites directly reflect cutaneous 
production and dietary intake and therefore is used as a marker to determine vitamin D 
sufficiency status.96, 97  25(OH)D3 is far more abundant in circulation than 25(OH)D2, with a 
normal concentration of 20-100 ng/ml but a preferred range of 30-60 ng/ml.98  Circulating 
concentrations below 20 ng/ml are considered deficient, 21-29 ng/ml insufficient, and above 30 
ng/ml sufficient.98-100  As reviewed by Holick, a high prevalence of inadequate 25(OH)D levels 
has been documented for many different populations: young and old, healthy and ill, white and 
non-white, in the United States and abroad.101  The prevalence of inadequate 25(OH)D levels in 
the United States is estimated to be more than 35% in healthy young adults (18 to 29 years) 
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 and as high as 60% in hospitalized patients. Studies of osteoporotic postmenopausal women 
have reported values ranging from 50% to 75%. Among those over age 50 hospitalized with 
non-traumatic fractures, 97% had 25(OH)D levels below 30 ng/ml. Inadequate 25(OH)D is even 
more prevalent among non-white populations where 42% of black women aged 15 to 49 years 
had levels below 15 ng/ml and 84% of elderly black individuals had levels below 20 ng/ml.101 
25(OH)D is subsequently hydroxylized in the kidney, as well as other tissues, into its 
most biologically active form, 1,25(OH)2D.95  Circulating concentrations of 1,25(OH)2D are 1000 
times lower than that of 25(OH)D.102  Renal production of 1,25(OH)2D is tightly regulated by 
PTH through end product inhibition (i.e. a negative feedback loop) by 1,25(OH)2D. PTH increase 
with higher 25(OH)D levels and stabilizes at a 25(OH)D concentration of 30-40 ng/ml.98, 103  
Other regulators include calcium, phosphate, growth hormone, and prolactin.95, 96  
Biological activities of 1,25(OH)2D are mediated by vitamin D receptors in the target 
tissues.104-106  Animal models have shown that normal and cancerous mammary cells have the 
ability to convert 25(OH)D into 1,25(OH)2D.107, 108  Breast cells contain the VDR which becomes 
activated through interaction with 1,25(OH)2D and can inhibit cellular proliferation and induce 
differentiation and apoptosis in normal mammary gland and breast cancer cells.105, 109  A 
possible mechanism for the malignant transformation of breast cells is through insufficient 
25(OH)D levels which limits the synthesis of 1,25(OH)2D, thus preventing activation of the VDR 
to regulate the cell cycle.98   Furthermore, 1,25(OH)2D down regulates inflammatory markers 
which has an anti-proliferative effect.103  Hence, vitamin D has the potential to influence the 
development of breast cancer.  
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Figure 2. Vitamin D metabolism and action in bone, intestine, and breast tissue  
In addition to the kidney, active vitamin D (1,25(OH)2D) is produced locally in the breast where it interacts 
with the VDR to regulating genes that control cellular proliferation, inhibit angiogenesis, and induce 
differentiation and apoptosis. Subsequently, 1,25(OH)2D is rendered biologically inert through catabolism. 
In the small intestine, 1,25(OH)2D enhances intestinal calcium absorption through interaction with the 
VDR which aids in the expression of the calcium binding channel and the calcium-binding protein. In 
bone, along with PTH, 1,25(OH)2D interacts with the VDR on osteoblasts, causing expression of RANKL 
which binds to its receptor RANK on preosteoclasts, and initiates the transition to mature osteoclasts. 
Osteoclasts promote bone mineralization by removing Ca++ and phosphorus from bone in order to 
maintain circulating levels of these minerals.98, 110 
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 2.4.2 Ecologic Evidence 
Indeed, ecologic data have shown that vitamin D from UV-B radiation is associated with a 
reduction in breast cancer incidence and mortality. Populations living at sunny lower latitudes 
(regions with higher levels of solar UV-B radiation) have higher circulating levels of 25(OH)D,111 
have decreased breast cancer risk,112, 113 and lower mortality rates114-118 compared with 
populations living at higher latitudes (regions with lower levels of UV-B radiation). These finding 
suggest that part of the relation between sun exposure and breast cancer risk could be 
explained by the vitamin D metabolic pathway. The major limitation of such studies however is 
the potential for ecologic fallacy in which the observed statistical association at the population 
level does not necessarily represent the true association present at the individual level. 
2.4.3 Studies of Dietary Intake 
The potentially protective effects of vitamin D from dietary sources on breast cancer risk were 
investigated by case control119, 120 and cohort studies,121-125 and most recently randomized 
controlled trials.126, 127  Evidence of a role for vitamin D in reducing breast cancer risk is mixed. 
The randomized trial by Lappe et al. found a statistically significant reduced risk of overall 
cancer with combined daily calcium (1500 mg) and vitamin D (1100 IU) supplementation among 
postmenopausal women over age 55.127  The findings of the Women’s Health Initiative 
randomized trial showed no association with breast cancer (HR 0.96, 95%CI 0.85-1.09), 
however the dose of vitamin D (400 IU/day) is not thought to have been high enough.126  The 
Nurses’ Health Study found vitamin D intake to be inversely associated with breast cancer risk, 
but this effect was seen in premenopausal women only (RR 0.66, 95%CI 0.43-1.00).125  Other 
prospective observational studies of dietary intake found no association or a weak association 
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 that lacked statistical significance. Such studies are limited in their ability to quantify dietary 
intake and may not translate into physiologic levels. 
2.4.4 Biomarker Studies 
Given the difficulty in accurately estimating vitamin D intake from diet, and the tight physiologic 
control of 1,25(OH)2D, studies measuring circulating levels of 25(OH)D to determine vitamin D 
status are preferred. There has been much debate, however, surrounding the proper method of 
measurement for 25(OH)D, which is complicated further due to its two circulating forms, D2 and 
D3. While HPLC is considered to be the gold standard as it is able to quantify both metabolites, 
it is expensive, time consuming, requires a large sample, and is not readily available. Therefore 
alternatives such as the radio-immune assay (RIA) and enzyme immunoassay (EIA) are widely 
used. Reports from DEQAS (Vitamin D External Quality Assessment Scheme), an international 
laboratory quality control initiative, indicates that some assays routinely over estimate 25(OH)D 
levels.128  Furthermore, while various assay manufactures claim to measure total circulating 
25(OH)D (i.e. 100% cross-reactivity with both 25(OH)D2 and D3) only one assay, the Diasorin 
RIA, was found to accurately measure 25(OH)D by detecting both metabolites in human 
serum.129  Secondary hyperparathyroidism in individuals with low levels of 25(OH)D, leads to 
normal or elevated 1,25(OH)2D levels and hence 1,25(OH)2D should not be used as a measure 
of vitamin D status.101  Because breast tissue acquires 25(OH)D from blood and converts it to 
1,25(OH)2D locally, circulating levels of 25(OH)D is the appropriate measure to study the effect 
of vitamin D on the risk of breast cancer. 
Six studies, including one pooled analysis, have investigated the association of 25(OH)D 
concentration to breast cancer risk and are summarized in Table 2. Important covariates of 
vitamin D status including age, BMI, race, and season of blood draw were adjusted for as 
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 appropriate. Most recently, a case-cohort study from the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial found no association overall among women 55-74 years (RR 
1.04 for < 18.3 vs. ≥ 33.7 ng/ml, 95%CI 0.75-1.45,) or when limited to women aged 60 and older 
(results not reported).130  The only other prospective study, a matched nested case-control from 
the Nurses’ Health Study, found a modest reduction in breast cancer risk with high levels of 
25(OH)D (RR 0.73 for ≥ 42 vs. ≤ 22 ng/ml, 95%CI 0.49-1.07, ptrend=0.06). The association was 
stronger among women 60 and older (283 cases) in the highest (≥ 42 ng/ml) versus the lowest 
(≤ 22 ng/ml) quintile although the results were not statistically significant (RR 0.57, 95%CI 0.31-
1.04, ptrend=0.03).131   
Two case-control studies have reported a positive association between low levels of 
measured 25(OH)D and increased breast cancer risk. A population-based matched case-control 
study among postmenopausal women found an odds ratio (OR) of 0.31 (95%CI 0.24-0.42) for 
the highest (≥ 30 ng/ml) versus the lowest (< 12 ng/ml) category of 25(OH)D.132  A matched 
case-control study with 179 cases found an overall odds ratio of 3.54 (95%CI 1.86-6.61) for 
breast cancer risk among individuals with < 20 ng/ml 25(OH)D compared to > 20 ng/ml.133  The 
study also found a five-fold risk of breast cancer among women in the lowest (< 20 ng/ml) 
versus the highest (> 60 ng/ml) quartile of vitamin D levels (OR 5.83, 95%CI 2.31-14.7). One 
smaller matched case-control study (156 cases) found no difference in 25(OH)D levels between 
cases and controls (μ difference 0.87, 95%CI -0.47-2.21).134  The findings of case-control 
studies are of limited relevance to the development of breast cancer due to the fact that blood 
samples were collected after the cancer was diagnosed. The preventive effect of vitamin D may 
only be applicable during the early stages of carcinogenesis.135  
The only study to investigate estrogen receptor status and breast cancer risk for 
25(OH)D reported a borderline significant inverse association (ptrend=0.08) with ER-/PR-, 
however they had limited power and used a combined population of premenopausal and 
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postmenopausal women.131  This finding is inconsistent with the reported stronger association 
among older women who are far more likely to have ER+ opposed to ER- breast cancer. 
Furthermore, ER+ and ER- tumors likely have different etiologies.8 
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Table 2. Results and characteristics of studies investigating the association between endogenous 25(OH)D levels and 
incident breast cancer 
Author Study Design Case / 
Control /  
Population 
Comparisons Results 
 (95%CI) 
Matched on (M) /  
Adjusted for (A) 
Freedman 2008 
PLCO Cancer 
Screening Trial, 
US 
Frequency 
matched, 
case-cohort 
1005/1005 
 
Multi-racial 
Mixed-
menopausal 
Quintiles  
<18 vs. ≥34 ng/ml 
 
Aged 60+ 
 
RR=1.04 (0.7-1.4) 
 
No association 
M: age, year of study entry, 
season; A: BMI, menarche age, 
menopause age, HT, BBD, FH, 
parity/age first birth, smoking, 
alcohol, calcium intake 
Abbas 2008 
Population-
based, Germany 
Matched case-
control 
 
post-diagnosis 
samples 
1394/1365 
 
 
Post-
menopausal 
Categories = 5 
≥30 vs. <12 ng/ml 
 
OR=0.31 (0.2-0.4) 
M: season, age; A: menopause 
age, FH, BBD, parity, menarche 
age, breastfed, number of 
mammograms, HT, BMI, education, 
smoking   
Garland 2007* Pooled 
analysis 
 Quintiles  
Median ng/ml 
48 vs. 6 
 
OR=0.50 
(ptrend<0.001) 
 
Bertone-
Johnson 2005 
Nurses’ Health 
Study, US 
Nested 
matched case-
control 
701/724 
 
Multi-racial 
Mixed-
menopausal 
Quintiles 
≥42 vs. ≤22 ng/ml 
 
Aged 60+ 
 
RR=0.73 (0.5-1.1) 
 
RR=0.57 (0.3-1.0) 
 
M: age, menopause status, HT, 
season, fasting; A: BMI, parity, age 
first birth, FH, BBD, menarche age, 
menopause age, alcohol, α-
carotene, estradiol, HT duration   
Lowe 2005  
Hospital-based, 
UK 
Matched case-
control 
179/179 
 
Caucasian 
Mixed-
menopausal 
Quartiles 
<20 vs. >60 ng/ml 
 
 
 
OR=5.83 (2.3-14.7) 
 
M: season, age, menopause status 
Janowsky 1999 
Hospital based, 
US  
Case-control 
 
post-diagnosis 
samples 
131/149 
 
Caucasian 
Mixed-
menopausal 
 
Cases vs. 
Controls 
 
Mean difference = 
0.87 (-0.47-2.21) 
M: age, race, clinic, season 
*Pooled analysis included two studies; Berton-Johnson et.al and Lowe et.al.  
Abbreviations used: BBD, benign breast disease; BMI, body mass index; CI, confidence interval; FH, family history; HT, hormone therapy; OR, 
odds ratio; RR, relative risk  
 2.4.5 Summary 
Vitamin D has been shown to be inversely related to breast cancer through studies of ultraviolet 
radiation,112, 113 dietary intake,119, 121, 125, 127 and circulating concentrations.131-133  In addition, 
postmenopausal women are thought to be at increased risk of vitamin D deficiency and related 
health consequences.136  Insufficient vitamin D intake coupled with low sunlight exposure (the 
source of more than 90% of our vitamin D requirements), and the reduced ability of aged skin to 
synthesize cholecalciferol contributes significantly to vitamin D deficiency in this age group.137-139  
In light of the apparently contradictory findings from the Nurses’ Health Study, and given the 
heterogeneity of risk factors by estrogen receptor status, it becomes increasingly important to 
disentangle these effects. However, the relationship between serum 25(OH)D and breast 
cancer has never been studied solely in postmenopausal women by histological subtype.  
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2.5 FRACTIONAL CALCIUM ABSORPTION AND BREAST CANCER RISK 
2.5.1 Determinants of FCA 
Fractional calcium absorption, a measure of intestinal calcium absorption, varies widely from 
person to person. Among postmenopausal women, FCA values have been reported to range 
from 0.07 to 0.68 with an average of 0.27 ± 0.10 (SD).140  Given the high reproducibility of 
calcium absorption measures (r=0.8 over 8 weeks, r=0.5 over 5 years), the variation is thought 
to be largely due to biological need.141  Indeed, several factors have been shown to effect 
intestinal calcium absorption, including calcium intake, age, estrogen, and serum levels of the 
biologically active 1,25(OH)2D.  
By far, the most significant factor affecting intestinal calcium absorption is its hormonal 
regulator, 1,25(OH)2D.142-145  See Figure 2. Approximately 20% of the variation in calcium 
absorption between individuals can be explained by circulating 1,25(OH)2D.142  Some 
studies,142, 145, 146 but not all,147-153 have reported decreased levels of serum 1,25(OH)2D with 
age. Alternatively, some investigators have reported 25(OH)D, but not 1,25(OH)2D, to be highly 
and positively correlated with calcium absorption.152, 154-156  Serum 25(OH)D concentration was 
estimated to be responsible for 25% of the variation in calcium absorption,154 and has been 
proposed to be more biologically active in intestinal calcium absorption than 1,25(OH)2D.152  
Studies of treatment with 25(OH)D have been shown to increase both 1,25(OH)2D levels and 
calcium absorption.156-158  
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FCA is also affected by other factors. There is overwhelmingly consistent evidence that 
FCA varies inversely with calcium intake (i.e. low absorption values are associated with high 
 
 calcium intake and high absorption values are associated with low calcium intake).140, 145, 150, 159, 
160  In quantitative terms, with a daily intake of 200 mg of calcium, the mean absorption fraction 
was 0.45 compared to 0.15 at 2000 mg/day among non-estrogen deprived women.160  As much 
as 26% of the variation in calcium absorption among individuals is attributed to calcium intake 
(both dietary and supplemental).160 
It is well established that intestinal calcium absorption declines with increasing age.137, 
143, 145, 151, 160, 161  There is some debate however, as to whether there is a dual phase decrease 
which first occurs at menopause, and then subsequently with older age,160 or if there is a single 
menopause related decrease in calcium absorption that can be counteracted with hormone 
therapy.145  One study reported a decrease in calcium absorption of about 0.21% per year after 
age 40, with menopause itself responsible for a drop of 2.2%.160  A more recent and larger study 
reported a 30% decrease in intestinal calcium absorption among women greater than 75 years 
of age, in addition to the decline that occurs at menopause.143  Not all studies however, have 
reported an age related decrease in intestinal calcium absorption.150, 153  
Studies have not only shown that calcium absorption is lower in postmenopausal 
compared to premenopausal women, but that it can be reversed by estrogen replacement.162, 163  
Researchers are uncertain however, if the exogenous estrogen directly increases calcium 
absorption, or if it works through other mechanisms such as increasing the circulating levels of 
1,25(OH)2D.  
Two additional factors that have been associated with calcium absorption are body size 
and smoking. Height and weight, but not BMI were positively associated with FCA in a study of 
middle aged women even after adjustment for estrogen status.164  In a separate study of elderly 
adults (mean age 70), FCA was significantly (p<0.05) lower among smokers regardless of 
gender, age, and calcium and vitamin D intakes, and among the heaviest smokers (≥ 20 
cigarettes/day, ptrend<0.02).165  There is conflicting evidence regarding the effect of smoking on 
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 serum sex hormone levels, with reports of both increased and decreased levels among 
smokers.165  Given that estrogen depletion among postmenopausal women is known to 
decrease calcium absorption, the lower FCA among smokers may be caused by a similar 
mechanism, i.e. altered sex hormone levels.165  Other identified correlates of FCA include 
weight loss and bone mineral density.166 
2.5.2 Evidence of Tissue Resistance 
Intestinal calcium absorption has been considered a marker of tissue responsiveness to vitamin 
D and aging has been associated with reduced sensitivity to 1,25(OH)2D.167  The evidence 
supporting this claim is of varying strength. One study demonstrated unchanging calcium 
absorption with increasing age despite higher levels of 1,25(OH)2D, suggestive of intestinal 
resistance to 1,25(OH)2D with aging.150  Similarly, reduced calcium absorption was reported 
among non-estrogen users over age 75, despite unchanging 1,25(OH)2D or 25(OH)D levels.143  
Perhaps the most compelling findings are from a study by Pattanaungkul et al. which clearly 
shows that in young women (mean 29 years) FCA increases with increasing serum 
concentrations of 1,25(OH)2D, while the increase in FCA among elderly women (mean 73 
years) is significantly diminished (p=0.03) with increasing serum concentrations of 
1,25(OH)2D.168 
The actions of 1,25(OH)2D on the small intestine and other target tissues are mediated 
by the VDR, an intracellular protein, and are ultimately involved with calcium transport.169, 170 
Cellular responsiveness to 1,25(OH)2D is dependent on the concentrations of both the VDR and 
1,25(OH)2D.169  Consequently, changes in the intestinal VDR protein concentration may 
contribute to the decline in calcium absorption with age.151  While there has been a report of 
lower concentrations of intestinal VDR proteins with age, fractional calcium absorption remained 
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 unchanged with increasing age among elderly women, thus providing further evidence of an 
impaired intestinal response to 1,25(OH)2D with increasing age.153  Another study did not find 
lower VDR concentrations with age, but did find a decrease in calcium absorption that was only 
partially explained by changes in 1,25(OH)2D serum concentrations indicating some level of 
intestinal resistance to 1,25(OH)2D.151  Indeed, animal models have supported the theory of 
age-related resistance to 1,25(OH)2D. Old rats were not found to have lower VDR counts 
compared to young rats, however they did have significantly lower calcium absorption (46%) 
despite receiving supplemental 1,25(OH)2D to raise plasma levels.171 
Evidence from recent dietary studies of calcium and vitamin D provides additional 
support to the theory of intestinal resistance to vitamin D with age. The Nurses’ Health Study, a 
large prospective cohort study of over 88,000 women found an inverse association between 
breast cancer risk and vitamin D intake among premenopausal but not postmenopausal 
women.125  These findings were confirmed in the Women’s Health Study, which showed a lower 
risk of premenopausal but not postmenopausal breast cancer with higher vitamin D intake.122  
Similarly, the WHI randomized trial of calcium plus vitamin D in postmenopausal women did not 
report any significant influence of supplementation on breast cancer risk.126  
Other investigators have hypothesized that the age-related decline in calcium absorption 
is due to an estrogen deficiency induced decrease in intestinal response to 1,25(OH)2D.151  In 
support of this theory, a placebo controlled clinical trial found that both FCA and serum 
1,25(OH)2D concentration were increased after treatment with estrogen in postmenopausal 
osteoporotic women.172 
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 2.5.3 Summary 
Based upon the current evidence suggesting intestinal resistance to vitamin D with age, it is 
conceivable that other vitamin D sensitive tissues, such as breast tissue, may also have 
diminished response to vitamin D with aging. In fact, the decreased ability to absorb calcium 
with age, indicative of reduced gut tissue responsiveness to vitamin D, may be representative of 
other tissue’s impaired responsiveness. This relationship however, has never been studied. 
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2.6 BONE MINERAL DENSITY AND BREAST CANCER RISK  
2.6.1 Biologic Plausibility 
Bone remodeling is the process by which the two types of bone tissue (cancellous or trabecular 
bone and cortical or compact bone) renew themselves. Normal bone turnover involves the 
metabolism of bone-resorbing cells (osteoclasts) followed by bone-forming cells (osteoblasts).173 
Estrogen is integral to bone health, exerting a multitude of actions on bone tissues, with 
estrogen deprivation leading to accelerated bone loss.173  Bone strength is a reflection of both 
density and quality and is measured by several different methods. The assessment of bone 
strength can be either radiologic (i.e. bone mineral density), biochemical (i.e. markers of bone 
turnover), or histologic (i.e. bone biopsy for histomorphometry).173  Measures of bone mineral 
density are the least invasive and the most widely used in clinical practice. Dual-energy x-ray 
absorptiometry (DXA), the standard device used to measure bone mineral density, is highly 
precise with coefficients of variation ranging from 1-3% depending on the skeletal site.174 
Estrogen is thought to play a central role in the development of breast cancer due to its 
ability to stimulate proliferation of breast tissue.175  Factors that increase exposure of breast 
tissue to estrogens, such as early menarche, older age at first birth, or late menopause, are 
associated with breast cancer risk.176  Indeed, prolonged exposure to high levels of endogenous 
estrogens may increase breast cancer risk in postmenopausal women.177  However, it is difficult 
to classify a woman’s long-term exposure to endogenous estrogen by a single measurement 
because serum estrogen levels are highly variable over time.178 
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 Bone mineral density, on the other-hand, is hypothesized to be a surrogate measure of 
lifetime estrogen exposure.179  Bone contains estrogen receptors and is sensitive to circulating 
estrogen levels.180  BMD is positively correlated with endogenous estrogen levels,181 early 
menarche, parity, and the length of a woman’s reproductive lifecycle.182  In addition to the 
underlying age related decrease, BMD also decreases in postmenopausal women, mostly due 
to loss of ovarian estrogen beginning around the time of menopause. Even among 
postmenopausal women, however, the rate of bone loss is variable. Factors affecting 
postmenopausal bone loss include sustained estrogen exposure due to exogenous estrogen 
use and/or endogenous estrogen released from fat, age, BMI, calcium and vitamin D intake 
from dietary and supplemental sources, and level of physical activity.183 
2.6.2 Etiologic Studies 
As first proposed by Cauley and colleagues in the Study of Osteoporotic Fractures (SOF), 
increased BMD, reflecting high estrogen exposure throughout life, may be a predictor of future 
breast cancer occurrence.184  Bone mineral density and other related surrogate markers of long-
term estrogen exposure including height loss and history of fractures have been shown to be 
associated with the risk of breast cancer. Lower BMD (RR per 1 SD increase = 1.50, 95%CI 
1.16-1.95), greater height loss (OR 0.67 for -2.5cm vs. 0, 95%CI 0.47-0.96), and more recent 
fracture experience (OR 0.79 for <5yr vs. none, 95%CI 0.65-0.95), are each associated with a 
reduced risk of breast cancer.184, 185  Other studies of women who have experienced bone 
fractures late in life, an indicator of low BMD, have been noted to have a reduced risk of breast 
cancer.185-189  Several prospective studies have sought to confirm the association between high 
BMD and increased breast cancer risk, and found a similar or slightly weaker relationship.190-194   
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 Additionally, the risk of breast cancer related to BMD appears to differ by family history 
of breast cancer,190, 195 stage at diagnosis,196 and estrogen receptor status.197  The more recent 
studies have focused on the effect of circulating sex hormones, particularly estradiol and 
testosterone, on the association between BMD and breast cancer risk. Two studies found that 
the relationship between BMD and breast cancer was attenuated when endogenous hormone 
levels were controlled for.197, 198  However, in one study, when stratified by estradiol level, high 
BMD (> 0.62 g/cm2) was a significant predictor of breast cancer risk in individuals with low 
estradiol concentrations (HR 2.6 for ≤ 10pmol/l, 95%CI 1.2-5.7), but not associated in 
individuals with high estradiol concentrations (HR 0.9 or > 10pmol/l, 95%CI 0.4-1.8).199  Table 3 
provides an overview of the important characteristics of the published studies that have 
investigated the association between BMD and breast cancer risk along with details of the major 
findings.  
 Table 3. Population characteristics and results of studies assessing the association of bone mineral density and incident breast cancer 
Author Study Type / 
Length 
Study Population BMD Measure / Results* Adjustment Factors 
Population 
Proximal radius (SPA):Prospective 
cohort 
97 cases / 6854 cohort 
32 
Cauley 1996 
 
Study of Osteoporotic 
Fractures (SOF) 
 
 
3.2 years mean 
follow-up 
 
 
Postmenopausal, 65+ 
years, Caucasian, no HBC, 
excluded cases within first 
year, not currently on ERT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RR=1.3 (1.1-1.6) Multivariable adjustment did 
not affect study results. Q1 RR=1.00                Ptrend =.01 
Q2 RR=1.9 (1.0-3.7) 
Q3 RR=2.4 (1.3-4.7) 
Q4 RR=2.3 (1.2-4.5) 
Distal radius (SPA): 
RR=1.4 (1.1-1.7) 
Q1 RR=1.00                 Ptrend =.004 
Q2 RR=1.9 (1.0-3.7) 
Q3 RR=2.1 (1.1-3.9) 
Q4 RR=2.7 (1.4-5.1) 
Calcaneus (SPA): 
RR=1.2 (1.0-1.5) 
Q1 RR=1.00                 Ptrend =.01 
Q2 RR=2.1 (1.1-4.2) 
Q3 RR=2.4 (1.2-4.8) 
Q4 RR=2.5 (1.3-5.0) 
Femoral neck (DXA): 
RR=1.5 (1.2-1.9) 
Q1 RR=1.00                 Ptrend =.001 
Q2 RR=2.1 (0.8-5.6) 
Q3 RR=4.1 (1.6-10.0) 
Q4 RR=4.0 (1.6-9.7) 
Total spine (DXA): 
RR=1.4 (1.1-1.7) 
Q1 RR=1.00                 Ptrend =.01 
Q2 RR=1.8 (0.8-4.1) 
Q3 RR=1.5 (0.6-3.5) 
Q4 RR=3.3 (1.6-7.1) 
Prospective 
cohort  
91 cases / 1373 cohort  Second metacarpal (Radiograph):Zhang 1997 
 
Framingham Study  
 
 
22.1 years median 
follow-up 
 
Postmenopausal,  47-80 
years, no HBC, race 
unknown 
  
Q1 RR=1.0                    Ptrend =.001 Multivariable adjusted rate 
ratios did not affect results. Q2 RR=1.3 (0.6-2.8) 
Q3 RR=1.3 (0.6-2.7) 
Q4 RR=3.5 (1.8-6.8) 
 
 Table 3. continued 
BMD Site / Results* Author Study Type / 
Length 
Study Population Adjustment Factors 
Population 
Prospective 
cohort 
121 cases / 8065 cohort Proximal radius (SPA):
33 
Kuller 1997 
 
Study of Osteoporotic 
Fractures (SOF) 
 
 
3.2 years mean 
follow-up 
  
Postmenopausal,  65+ 
years, Caucasian, no HBC, 
excluded cases within first 
year 
  
Q1 IR=2.5 (1.5-4.3) Multivariable adjustment did 
not affect study results. Q2 IR=4.1 (2.1-6.2) 
Q3 IR=5.1 (3.5-7.4) 
Q4 IR=5.5 (3.9-7.8) 
Other sites were not presented 
 Prospective 
cohort 
104 cases / 7250 cohort Proximal radius (SPA):Lucas 1998  
35% increase in breast 
cancer relative risk per 1 SD 
increase in radial BMD 
based on multivariable 
adjusted models. 
 T1 RR=1.0  
Study of Osteoporotic 
Fractures (SOF) 
3.2 years mean 
follow-up 
Postmenopausal, 65+ years, 
Caucasian, no HBC, 
excluded cases within first 
year 
T2 RR=1.5 (0.9-2.6) 
T3 RR=1.8 (1.0-3.1) 
      Family history (+/-): 
      RR=4.2 (2.0-9.0) T3+ vs. T1- 
 Distal radius (SPA): 
 T1 RR=1.0 
T2 RR=1.6 (0.9-2.8) 
T3 RR=2.4 (1.4-4.2) 
Calcaneus (SPA): 
T1 RR=1.0 
T2 RR=1.5 (0.8-2.5) 
T3 RR=1.5 (0.9-2.7) 
Nested case-
control 
30 cases / 120 controls Femoral neck (DXA):Nguyen 2000 
 
Dubbo Osteoporosis Epi 
Study (DOES) 
  
Cases self-
reported at 
baseline  
 
Postmenopausal, 60+ years  
 Matched on age and weight 
(±3kg) RR=1.4 (1.0-2.3) 
Lumbar spine (DXA): Years of ovulation, BMI, age 
at menarche, parity, HRT 
use in past 5 years 
RR=2.0 (1.3-3.0) 
Prospective 
cohort  
131 cases / 8203 cohort Proximal femur (DXA):Buista 2001 
 
Fracture Intervention 
Trial (FIT) 
 
 
3.7 years mean 
follow-up 
 
Postmenopausal, 54-80 
years, majority Caucasian, 
no HBC, excluded cases 
within first 6 months 
 Multivariable adjustment 
Q1 RR=1.0  
Q2 RR=1.9 (1.1-3.2) 
Q3 RR=1.5 (0.8-2.6) 
Q4 RR=1.5 (0.8-2.7) 
     Family history (+/-): 
     Q1+ RR=1.8 (0.6-4.8)  
     Q2-4+ RR=2.3 (1.1-4.5) 
     Q1- RR=1.0 
     Q2-4- RR=1.7 (1.0-2.9) 
 
 Table 3. continued 
BMD Measure / Results* Author Study Type / 
Length 
Study Population Adjustment Factors 
Population 
Case-cohort study 109 cases / 173 controls  Proximal femur (DXA):
34 
Buistb 2001 
 
Fracture Intervention 
Trial (FIT) 
 
  
3.7 years mean 
follow-up 
 
Postmenopausal, 54-80 
years, majority Caucasian, 
no HBC, excluded cases 
within first 6 months 
 The relationship between 
BMD and breast cancer risk 
is truncated when measured 
hormone levels and other 
covariates are controlled for. 
Q1 RR=1.0 
Q2 RR=2.1 (1.0-4.8) 
Q3 RR=1.5 (0.6-3.6) 
Q4 RR=1.4 (0.5-4.0)  
 
 
 Prospective 
cohort  
315 cases / 8905 cohort Proximal radius (SPA):  Zmuda 2001 
Multivariable adjustment did 
not affect study results. 
 Q1 RR=1.0  
Study of Osteoporotic 
Fractures (SOF) 
6.5 years mean 
follow-up 
Postmenopausal women 
aged 65+, Caucasian, no 
HBC, excluded cases within 
first year 
Q2 RR=1.6 (1.1-2.3) 
Q3 RR=1.7 (1.2-2.4) 
 Q4 RR=2.0 (1.4-2.9) 
 Distal radius (SPA): 
Q1 RR=1.0 
Q2 RR=1.4 (1.0-2.1) 
Q3 RR=1.4 (0.9-1.9) 
Q4 RR=2.0 (1.4-2.9) 
Calcaneus (SPA): 
Q1 RR=1.0 
Q2 RR=1.1 (0.8-1.7) 
Q3 RR=1.8 (1.3-2.6) 
Q4 RR=1.8 (1.3-2.6) 
 
Case-control 126 cases / 126 controls Lumbar spine:Ganry 2001 
 
 
 
Postmenopausal, age 
unknown  
 significant  
Femoral neck: NS Limited information based on 
abstract only Trochanter: significant 
Ward’s Triangle: significant 
Q4 vs. Q1 RR range (2.5-4.8) 
 
 
 
 
 
 Table 3. continued 
BMD Measure / Results* Author Study Type / 
Length 
Study Population Adjustment Factors 
Population 
Prospective 
cohort 
41 cases / 1091 cohort Wrist:
35 
Nelson 2002 
 
NHANES I 
Epidemiologic Followup 
Study 
 
 
19 years follow-up 
 
 
Postmenopausal, 55+ years, 
majority Caucasian, no HBC 
  
Q1 RR=1.0                Ptrend =.04 Age, race, and BMI 
Q2 RR=0.2 (p=0.03) 
Q3 RR=1.6 (p=0.23) 
Q4 RR=1.7 (p=0.26) 
 Prospective 
cohort  
74 cases / 3107 cohort Lumbar spine (DXA):Van der Klift 2003  
Multivariable adjustment did 
not affect study results. 
  T1 RR=1.5 (0.8-2.9)  
Rotterdam Study 6.5 years mean 
follow-up 
Postmenopausal women 
55+ years, no HBC, race not 
addressed 
T2 RR=1.0 
  T3 RR=2.1 (1.1-3.7) 
 Femoral neck (DXA): 
T1 RR 0.8 (0.4-1.4) 
T2 RR=1.0 
T3 RR 1.0 (0.6-1.7) 
Intertrochanteric (DXA): 
T1 RR 0.7 (0.4-1.3) 
T2 RR=1.0 
T3 RR 1.1 (0.6-1.9) 
Hospital based 
matched case-
control 
221 cases / 197 controls Proximal radius (DXA):Nelson 2004 
 
 
 
Caucasian, mixed 
menopausal status, aged 
40-85 years, no HBC, no 
steroids/bisphosphonates 
>1month 
 Matched on ethnicity and 
age OR=2.0 (1.1-3.6)  
Z-score >0 vs. <0  
BMI, menopausal status, 
age, HRT use 
 
 
 
 
 
 Table 3. continued 
BMD Measure / Results* Author Study Type / 
Length 
Study Population Adjustment Factors 
Population 
Prospective 
cohort  
45 cases / 1504 cohort Femoral neck (DXA):
36 
Ganry 2004 
 
Epidemiologic Study of 
Osteoporosis (EPIDOS)  
 
 
7 years mean 
follow-up 
 
Postmenopausal, 75+ years, 
Caucasian, no HBC, 
excluded cases within first 6 
months, no metabolic bone 
disease 
 Multivariable adjustment 
T1 RR=1.0 
T2 RR=2.6 (1.1-6.8) 
T3 RR=3.1 (1.2-7.8) 
Trochanter (DXA): 
T1 RR=1.0 
T2 RR=1.4 (0.6-3.3) 
T3 RR=2.2 (1.1-4.8) 
Ward’s Triangle (DXA): 
T1 RR=1.0 
T2 RR=1.6 (0.7-3.5) 
T3 RR=2.2 (1.0-4.8) 
Nested case-
control 
208 cases / 436 controls Total hip (DXA):Kerlikowske 2005 
 
San Francisco 
Mammography Registry 
 
2 years mean 
follow-up 
 
Aged 28+ years, no HBC, 
excluded breast 
augmentation/mastectomy  
 Age, family history, age at 
first live birth/nulliparous, 
breast density, race, BMI 
Q1 OR=1.0 
Q2 OR=1.1 (0.7-1.9) 
Q3 OR=1.3 (0.8-2.1) 
Q4 OR=1.2 (0.7-2.1) 
Prospective 
cohort 
87 cases / 3,013 cohort Lumbar spine (DXA):Stewart 2005 
 
 9.7 years mean 
follow-up 
 
Peri/early-menopausal, 45-
54 years, no HBC 
 Age, height, weight, 
menopausal status, HRT 
use 
RR=1.2 (1.0-1.5) / 1 SD decrease 
Femoral neck (DXA): 
RR=1.2 (0.9-1.5) / 1 SD decrease 
Case-cohort 196 cases / 378 controls Distal radius (SPA):Cummings 2005 
 
Study of Osteoporotic 
Fractures (SOF) 
 
 
10.5 years follow-
up 
 
Postmenopausal, 65+ years, 
no ERT,  
 Age, weight, education, 
testosterone, estradiol       Estrogen Receptor Positive 
     RR=1.2 (0.9-1.5)/1SD increase 
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Table 3. continued 
Author 
Population 
Study Type / 
Length 
Study Population BMD Measure / Results* Adjustment Factors 
Cauley 2007 
 
Multiple Outcomes of 
Raloxifene Evaluation 
(MORE) & Continuing 
Outcomes Relevant to 
Evista (CORE) 
 
 
Clinical Trial – 
Placebo arm 
13,698 py follow-
up 
65 cases / 2,511 controls 
 
Postmenopausal, ≤80 years, 
>2 years past menopause, 
osteoporotic, no 
HBC/endometrial 
cancer/stroke/venous 
thromboembolism in past 10 
years  
Femoral neck (DXA): 
     Low estradiol (≤10pmol/l) 
          RR=2.6 (1.2-5.7) 
          >0.62/≤0.62 (g/cm2) 
     High estradiol (>10pmol/l) 
          RR=0.9 (0.4-1.8) 
          >0.62/≤0.62 (g/cm2) 
Lumbar spine (DXA): 
not associated 
Age, family history, estradiol, 
estradiol-BMD interaction 
term 
Hadji 2007 
 
Marburg Breast Cancer 
& Osteoporosis Trial 
(MABOT) 
 
 
Case-control 242 cases / 2250 controls 
(matched analysis = 242 
controls) 
 
Untreated cases, no family 
history, aged 22-88 years 
Calcaneus (Ultrasonometry): 
Q1 OR=1.0                
Q2 OR=1.9 (1.1-3.2) 
Q3 OR=2.3 (1.3-3.9) 
Q4 OR=2.9 (1.7-5.0) 
T-score ptrend = <0.001 
Post-matched (1:1) on age, 
body weight, height, BMI, 
duration of estrogen 
exposure (endogenous and 
exogenous), estrogen use, 
age at menarche, age at 
menopause, parity, and 
breast feeding 
* Includes carcinoma in situ along with invasive breast cancer cases  
Abbreviations used: ERT, estrogen replacement therapy; DXA, dual energy x-ray absorptiometry; HBC, history of breast cancer; 
IR, incident rate = cases/1000 person years; OR, odds ratio; RR, relative risk; SPA, single photon absorptiometry 
 2.6.3 Variation in BMD Measure 
BMD has been investigated at a number of skeletal sites covering six body regions. These 
regions are the forearm (sites include the proximal radius),184, 195, 196, 200, 201 wrist (distal 
radius),184, 192, 195-197 hand (second metacarpal),194 spine (total spine and lumbar spine),184, 193, 199, 
202-204 hip (total hip, femoral neck, proximal femur, intertrochanteric, trochanter, and Ward’s 
triangle),184, 190, 191, 193, 198, 199, 202-205 and the heel (calcaneus).184, 195, 196, 206  Results of prospective 
studies reporting relative risks for individual skeletal sites are highlighted in Figure 3. 
The literature is fairly consistent in its assessment of the increasing risk of breast cancer 
with higher BMD measurements and these results hold for a variety of skeletal sites. The 
magnitude of the results, however vary by study and by skeletal site and are at best moderate to 
weak in their association. Peripheral skeletal sites and the lumbar spine (which have more 
trabecular bone and may therefore be more sensitive to estrogen) have been proposed to be 
better predictors of breast cancer risk than measurements of the hip, since it is a major load-
bearing site and potentially more affected by lifestyle differences.201  The two studies utilizing 
the Fracture Intervention Trial cohort reported a distinct threshold effect, while the other studies 
showed a more gradual increase with increasing level of BMD.190, 198  The strongest results are 
found when several skeletal sites are assessed in conjunction with one another. Because BMD 
can vary from one skeletal site to another on a single woman, Kuller et al. investigated the effect 
of low BMD at all sites versus high BMD at one or more sites and found that women with low 
BMD at several skeletal locations were highly protected against breast cancer compared to a 
woman with any measure of high BMD (RR=0.23, 95%CI 0.07-0.72).200  Some studies have 
found no association.204, 205  There are study specific issues that may have contributed to the 
inconsistencies in the findings, such as differences in skeletal region measured, bone mass 
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measurement methods, and characteristics of the populations studied, including inclusion 
criteria, sample size, and length of follow-up.  
Although the relationship between higher BMD and an increased risk of breast cancer in 
postmenopausal women has been well studied, the association is moderate at best, and critics 
still question the validity and/or biologic plausibility of these findings.207  One reason that a 
stronger association has not been documented, may be that even among women with low BMD, 
their exposure to estrogen has been sustained in a manner that negates the protective effect of 
having a lower BMD. Or conversely, among women with a higher BMD, their estrogen exposure 
has been diminished so that their increased risk of breast cancer has been attenuated. By 
looking at a women’s change in postmenopausal BMD level, it may be possible to relate BMD to 
risk of breast cancer in a way that accounts for sustained estrogen exposure. The one study to 
have looked at change in BMD over 6.9 years and the risk of breast cancer did so only among 
peri-postmenopausal women aged 45-54.204  They found no relationship with a mean follow-up 
of 9.7 years. The HR (95%CI) for 1 SD change in BMD at the spine was 1.17 (0.80-1.71) and 
1.15 (0.79-1.68) at the femoral neck. Given there were only 34 incident breast cancer cases, 
power was low and likely inadequate to detect a difference. 
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Figure 3. Relative risk of breast cancer for measures of bone mineral density from prospective cohort studies  
Comparisons groups are study specific and between the highest and lowest BMD category. Markers indicate point estimates; symbols designate 
cohorts:●=SOF, ■=EPIDOS, ▲=population based, ▬=Rotterdam, ◊=FIT, x=Framingham. Vertical lines represent 95% confidence intervals. BMD 
skeletal sites: Cal=calcaneus, DR=distal radius, FN=femoral neck, Int=Intertrochanteric, LS=lumbar spine, PF=proximal femur, PR=proximal 
radius, SM=second metacarpal, Tro=trochanter, WT=Ward’s triangle. 
 2.6.4 Summary 
While the proportion of elderly women with high bone density in the general population is less 
than 5%, the risk of breast cancer attributable to BMD is approximated to be 21%.203  Moreover, 
a recent analysis from the Women’s Health Study found that BMD predicted breast cancer risk 
independently of Gail score.208  There are many risk factors for breast cancer, and bone mineral 
density is just one of them. Because of its close ties to estrogen exposure, BMD may help to 
elucidate the underlying biology linking estrogen and breast cancer. BMD also has the potential 
to be an important and easily measured marker of breast cancer risk, if it is found to be a 
reliable predictor. There is much to be clarified concerning the strength of the relationship 
between BMD and breast cancer including the short-term versus the long-term risk associated 
with elevated BMD and if the rate of bone loss might be a better surrogate of estrogen 
exposure. 
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2.7 SUMMARY 
Figure 2As highlighted in , the role of vitamin D in the body varies widely from building bone to 
regulating gene expression. Aside from its function in calcium homeostasis, the action of vitamin 
D in the breast is completely separate. Maintaining adequate levels of vitamin D has the 
potential to prevent breast cancer through control of cellular processes including differentiation, 
proliferation, and apoptosis. The few existing studies of circulating 25(OH)D and risk of breast 
cancer have produced inconsistent results which are likely due to their inadequate size and/or 
design. Alternatively, lack of findings regarding risk of breast cancer in older women could be a 
result of lost sensitivity to 1,25(OH)2D with age. FCA may be an easily measured surrogate for 
general tissue responsiveness to 1,25(OH)2D.  
Bone mineral density, a marker of lifetime estrogen exposure, has been shown to be a 
moderately weak predictor of breast cancer among postmenopausal women over a relatively 
short period of time. However, the association is not as strong as expected. Additional studies 
are needed to determine if the relationship is maintained/strengthened/weakened with longer 
follow-up, and if other measures of BMD might be better at predicting breast cancer risk.   
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 3.0  SPECIFIC AIMS AND HYPOTHESES 
The following specific aims and hypotheses are proposed to address the areas requiring 
additional research identified above. 
1) To examine the association between serum concentrations of 25(OH)D and the 
risk of ER+ breast cancer among postmenopausal women. It is hypothesized 
that postmenopausal women with a low serum concentration of 25(OH)D will have 
an increased risk of breast cancer. 
a. Secondary aims are to test the hypotheses that this association differs by age 
and obesity. Further hypotheses are that the inverse association between low 
serum levels of 25(OH)D and higher breast cancer risk will be stronger 
among older and obese women. 
2) To examine the association between fractional calcium absorption and the risk 
of breast cancer among postmenopausal women. It is hypothesized that 
postmenopausal women with lower fractional calcium absorption are at increased 
risk of breast cancer.  
a. Secondary aims are to test the hypotheses that this association differs for  
ER+ cancers and by calcium intake. Further hypotheses are that the inverse 
association between low FCA and higher breast cancer risk will not differ for 
ER+ cancers, and that by category of calcium intake, women with low FCA 
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 will have an increased risk of breast cancer compared to women with high 
FCA. 
3) To assess whether the positive association between higher bone mineral 
density and increased breast cancer risk is maintained over a longer follow-up 
period, and if a measure of BMD change strengthens the association. 
Specifically, does a repeated bone mineral density measure (i.e. annualized percent 
change) enhance the prediction of breast cancer over that of a single measure and 
what is the association between change in BMD and breast cancer risk? It is 
hypothesized that postmenopausal women with a high vs. low BMD will have an 
increased risk of breast cancer. Furthermore, it is hypothesized that a lower rate of 
bone loss will be associated with an increased risk of breast cancer. 
a. Secondary aims are to test the hypotheses that this association differs for 
ER+ cancers and by family history of breast cancer. Further hypotheses are 
that the positive association between high BMD and increased breast cancer 
risk will be stronger for ER+ cancers and those with a positive family history 
of breast cancer.  
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 4.1 ABSTRACT 
Evidence suggests that vitamin D may reduce the incidence of breast cancer. The few 
epidemiologic studies that have investigated the relationship between circulating levels of 25-
hydroxyvitamin D [25(OH)D] and breast cancer risk have produced inconsistent results. We 
examined the subsequent risk of estrogen receptor positive (ER+) breast cancer related to 
serum levels of 25(OH)D in a case-cohort study within the Study of Osteoporotic Fractures 
(SOF), a prospective cohort of 9,704 postmenopausal, Caucasian women aged 65 and over. 
Serum 25(OH)D level was measured for 170 incident ER+ breast cancer cases and a random 
subcohort (n=332) of SOF participants using serum specimens collected at baseline (1988-
1989). A case-cohort analysis was performed to compute relative risks of breast cancer and 
95% confidence intervals. Mean time between blood draw and diagnosis was 6.0 years. The 
median 25(OH)D level was 27.5 ng/ml and did not differ between cases and non-cases (p=0.5). 
Low levels of 25(OH)D were not associated with an increased risk of breast cancer. Compared 
to women with sufficient levels of 25(OH)D (≥ 30 ng/ml), women with lower levels (20-30 and < 
20 ng/ml) had relative risks (95%CI) of 0.94 (0.61-1.46) and 1.15 (0.63-2.12), respectively 
(ptrend=0.8) in multivariable models adjusted for age (as timescale), clinic site, season of blood 
draw, BMI, smoking history, and estrogen therapy (ET). The findings of this prospective study of 
postmenopausal women are not supportive of an overall association between serum 25(OH)D 
concentration and the development of ER+ breast cancer. 
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 4.2 INTRODUCTION 
Evidence of the inverse association between vitamin D and breast cancer incidence and 
mortality has been shown through ecological studies of ultraviolet radiation. Populations living at 
sunny lower latitudes (regions with higher levels of solar UV-B radiation) have higher circulating 
levels of 25(OH)D,111 have decreased breast cancer risk,112, 113 and lower mortality rates114-118 
compared with populations living at higher latitudes (regions with lower levels of UV-B 
radiation). Studies of vitamin D intake from dietary and supplemental sources have reported 
mixed findings.119, 121-125  A recent randomized controlled trial (RCT) of calcium and vitamin D 
supplementation from the Women’s Health Initiative (WHI) reported no association with breast 
cancer, but the low dose of vitamin D used (400 IU) was inadequate to raise vitamin D 
concentrations to a sufficient level.126  
25-hydroxyvitamin D is the principal circulating vitamin D metabolite, directly reflecting 
both cutaneous production and dietary intake and is therefore the measure used to determine 
vitamin D sufficiency status.96  1,25-dihydroxyvitamin D [1,25(OH)2D] is the biologically active 
form of vitamin D95 and its activities are mediated by vitamin D receptors (VDR) in target 
tissues.104-106  Both normal and cancerous mammary cells have the ability to convert 25(OH)D 
into 1,25(OH)2D.107  Breast cells contain the VDR which becomes activated through interaction 
with 1,25(OH)2D and can inhibit cellular proliferation and induce differentiation and apoptosis in 
normal mammary gland and breast cancer cells.105, 109  A possible mechanism for the malignant 
transformation of breast cells is through insufficient 25(OH)D levels which limits the synthesis of 
1,25(OH)2D, thus preventing activation of the VDR to regulate the cell cycle.98   Therefore, 
vitamin D has the potential to influence the development of breast cancer.  
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  More than 50% of women, aged 60+ years, who were surveyed in the Third National 
Health and Nutrition Examination Survey were found to have inadequate serum 25(OH)D levels 
(i.e. < 62.5 nmol/L or 25.0 ng/ml) during the summer months at northern latitudes in the United 
States.209  Despite the high prevalence of low vitamin D status among older women, the 
association between circulating 25(OH)D and breast cancer risk is under-studied. The few prior 
studies have produced inconsistent results and, have been limited by combined premenopausal 
and postmenopausal populations130, 131, 133, 134 and cross-sectional case-control design.132-134  In 
fact, the association has never been investigated prospectively among postmenopausal women 
by histological subtype. This is an important distinction given that the majority of 
postmenopausal cancers are ER+, and that ER+ and ER- tumors likely have different 
etiologies.8  We undertook a case-cohort study to investigate to the risk of ER+ breast cancer 
associated with serum 25(OH)D concentrations among postmenopausal women. Specifically we 
tested the hypothesis that low levels of 25(OH)D will be associated with an increased risk of 
ER+ breast cancer. We also tested whether this association differed by age or obesity as 
secondary aims. 
4.3 METHODS 
4.3.1 Study Population 
The Study of Osteoporotic Fractures is a longitudinal cohort of 9,704 community-dwelling, 
Caucasian, postmenopausal women aged 65 and over who were recruited at 4 US clinical 
centers between 1986 and 1988. Women with a history of bilateral hip replacements and those 
who were unable to walk unassisted were excluded.210  At the baseline examination, women 
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 provided informed consent and risk factor and health measures were collected through physical 
measurements, questionnaires, and functional assessments. Serum samples were also 
obtained and immediately frozen at -20oC for no more than two weeks before being stored in 
liquid nitrogen at -190oC. 
4.3.2 Study Design  
The study is a case-cohort design,211 and is a secondary analysis of an existing case-cohort 
within SOF. The original study investigated the relationship of serum sex hormone levels and 
ER+ breast cancer risk.197  The original subcohort was a random sample of the entire SOF 
cohort. The original case group included all incident ER+ breast cancer cases validated through 
December 2000 when the case-cohort study was formed.  
4.3.3 Study Subjects  
Participants in this study were part of a previous case-cohort study. Incident breast cancer 
cases were defined by the diagnosis of estrogen receptor positive breast cancer occurring after 
the baseline examination. All incident cases with sufficient stored serum were included (n=160). 
A random subcohort of 363 women, with available serum, was chosen and formed the 
comparison group (subcohort), which included 15 cases. Twenty individuals reporting a prior 
history of breast cancer at baseline were excluded from this analysis. A single case subject was 
excluded due to a missing 25(OH)D measure. The final study was therefore comprised of 332 
subcohort non-cases, 14 subcohort cases, and 156 cases from outside the subcohort.  
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 4.3.4 Serum 25(OH)D Laboratory Measurement 
Serum 25(OH)D was measured by the designated Reproductive Endocrine Research 
Laboratory of the University of Southern California under the direction of Frank Stanczyk, PhD. 
Specimens were shipped via overnight courier in a Styrofoam box packed with dry ice, and 
arrived frozen and undamaged. The laboratory stored the samples at -70°C until they were 
assayed using 25(OH)D RIA kits and reagents from Diasorin (Stillwater, MN). This kit effectively 
detects both the D2 and D3 forms of endogenous 25(OH)D in human serum and has been 
shown to produce more reliable results than other commercially available 25(OH)D kits.129  In 
order to minimize interassay variability, the same kit lot number was used to analyze all the 
samples. In addition, a single highly trained technician was used to carry out all the assays and 
was masked to subject identity and all participant characteristics including case-control status. 
Samples were labeled by number only. Assay methods were identical for cases and the 
subcohort and were completed in a single batch. The performance of the 25(OH)D RIA kit was 
first checked by completing an assay using the manufacturer provided quality control (QC) 
samples and confirming that the obtained values were within the expected range reported in the 
instruction manual. The samples for the assay were thawed by standing at room temperature 
before being mixed thoroughly by inversion. 25(OH)D was extracted from the calibrators, high 
and low level controls and study samples by first aliquoting 50 µl of each into separate tubes 
containing 500 µl of acetonitrile and then vortexing each tube. Following a centrifugation step, 
25 µl aliquots were taken from each of the supernatants and transferred into a new set of 
labeled tubes. RIA was carried out in the usual manner by addition of 125I-25(OH)D and 
25(OH)D antiserum, incubation, and addition of second antibody to separate the antibody-
bound and unbound 25(OH)D.  The tubes were then counted in a gamma counter, and results 
were calculated using an RIA program. The assay sensitivity was 1.5 ng/ml, and the interassay 
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 CVs 11.7%, 10.5%, 8.6% and 12.5% at 8.6, 22.7, 33.0 and 49.0 ng/ml, respectively. 
Comparison of the present RIA method with the liquid chromatography mass-spectroscopy (LC-
MS/MS) assay carried out at the Mayo Clinic Endocrine Laboratory (Rochester, MN) showed a 
high correlation (Spearman correlation r=0.92; p=<0.001) between 25(OH)D values measured 
by the two assay methods.212  Furthermore, there was no significant difference in the mean 
25(OH)D levels between the two methods (paired t-test, p=0.73). Approximately 5% of our study 
samples (n=25) were tested in a blinded duplicate fashion. The correlations of assay values 
determined in the duplicate samples were high (R2=0.76) (Appendix A). 
4.3.5 Covariate Information 
At the baseline examination (V1), participants completed a questionnaire and were interviewed. 
Demographic (age, education), reproductive history (menarche age, parity, age at first birth, 
number of live births, breastfeeding), height at age 25, menopausal status (menopause age, 
surgical vs. natural menopause), and breast cancer risk factor (benign breast disease, family 
history of breast cancer) data were collected. Women were asked about smoking status, alcohol 
use (average number of alcoholic drinks/week), and physical activity. Body weight was 
measured using a balance-beam scale. BMI was calculated by dividing the V1 weight (kg) by 
the square of height (m) at age 25 years. Bone mineral density (g/cm2) of the proximal femur 
was measured using dual-energy x-ray absorptiometry (QDR 1000, Hologic, Waltham, 
Massachusetts).210, 213  Exogenous estrogen use (i.e. ET) was defined as currently taking 
estrogen pills. Current supplemental vitamin D use was defined as taking vitamin D or a 
multivitamin containing vitamin D at least once per week. Calcium supplementation was 
determined by asking about current use at least once per week. Dietary calcium intake was 
estimated by using a validated 20-item Block semi-quantitative food-frequency questionnaire 
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 developed from the Second National Health and Nutrition Survey (NHANES II).214, 215  Total 
calcium intake was calculated by summing dietary calcium intake (mg/d) and daily dose of 
calcium supplements (mg/d). Month of blood draw was grouped into seasons of winter 
(December-February), spring (March-May), summer (June-August), and fall (September-
November). Variables were categorized based on common cutpoints (e.g. BMI) or the original 
response categories collapsed to prevent small cell counts (e.g. age at first birth). Continuous 
variables were additionally dichotomized at their median and/or divided into quartiles for analytic 
purposes. 
4.3.6 Incident Breast Cancer Ascertainment 
Follow-up occurred every four months by either postcard or telephone (98% complete) in 
addition to clinic visits approximately every 2 years. Breast cancer outcomes were ascertained 
through self-report or death certificate review and were adjudicated by physicians locally and 
centrally at the San Francisco Coordinating Center. Medical records and pathology reports were 
used to record information on date of breast cancer diagnosis, stage at diagnosis, and estrogen- 
and progesterone-receptor status.184 
4.3.7 Statistical Analysis 
Smoothed density plots and kernel density plots of serum 25(OH)D by age at baseline for the 
cases, subcohort cases, and the non-case subcohort were investigated (Appendix A). No 
meaningful differences in the distribution of the subcohort cases and non-subcohort cases were 
found. All subsequent analyses were conducted with a combined case group (n=170).  
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 As part of the preliminary data analysis, the distribution of baseline characteristics 
among the cases and the non-cases were compared by t-test for continuous variables and the 
chi-square test for categorical data. The median values of 25(OH)D were also compared by 
age, season of blood draw, vitamin D supplement use, and BMI using either the Wilcoxon rank 
sum test or the Kruskal-Wallis test. Supplemental vitamin D use, defined as taking vitamin D or 
a multivitamin containing vitamin D at least once per week, was assessed at the baseline 
examination and categorized as current/past/never user. The median difference in 25(OH)D 
level was evaluated by category of vitamin D supplementation. The log transformation of 
25(OH)D was investigated, however, it did not significantly improve normality, and therefore 
modeling was pursued with the non-transformed values (Appendix A). 
The main analysis estimated hazard ratios (HR) and 95% confidence intervals (95%CI) 
for the association of serum 25(OH)D level and with the risk of incident ER+ breast cancer using 
multivariable Cox proportional hazard regression models that include robust standard error 
estimates to account for the case-cohort design,211, 216 with age as the underlying time scale.217-
219  The analysis of a case-cohort study differs from that of a traditional cohort in that the 
denominator sums over subjects at risk in the subcohort rather than subjects at risk in the entire 
cohort. Subcohort members (cases and non-cases) contributed to the analysis over their entire 
time in the study whereas the cases outside the subcohort contributed only at their event time. 
At each event (failure), a risk set was formed which consisted of only the subcohort members 
(cases and non-cases) and any non-subcohort cases that failed at that time. The addition of 
non-subcohort cases at their respective event times results in non-nested risk sets. 
The level of the 25(OH)D serum marker was entered as a continuous variable to 
estimate the relative risk (RR) of breast cancer. Levels of vitamin D were also assessed as 
categories of deficient (< 20 ng/ml), insufficient (≥ 20 to < 30 ng/ml), and sufficient (≥ 30 
ng/ml).98  The relative risk of breast cancer, estimated as hazard ratios, was estimated for each 
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 category using the highest category as the reference and adjusting for covariates as necessary. 
Because laboratory measured vitamin D is a continuous measure with clinically important 
threshold values, cubic splines were fit to investigate non-linear effects. Restricted cubic splines 
allow continuous data to fit within the Cox model without assuming linearity.220  Cubic splines are 
piecewise polynomial functions that are constrained to join at control points (knots) in the data. 
Forcing the first and second derivatives of the functions to agree at the knots results in smooth 
splines. RCS (restricted cubic splines), a SAS macro, was used to create the cubic splines.221 
Knots were placed at typical clinical cut-points used to assess vitamin D status (15, 20, and 30 
ng/ml).98-100  To ensure that the location of the knots did not influence the results, a spline with 4 
knots placed at standard percentiles (5, 25, 75, 95) was also investigated.221  
All models were adjusted for SOF clinic site and season of blood draw. Preliminary 
multivariable models were fit separately and included potential confounders described above 
based on their significance (p=0.1) in the univariate analyses as well as a priori established 
breast cancer risk factors. In situations where variables are correlated, e.g. various measures of 
body size, variable choice was based on statistical association, scientific knowledge, and/or 
variable distribution. The potential correlation of continuous modeling covariates was 
investigated using a covariance matrix (Appendix A). Dummy variables were created for 
categorical variables as appropriate. Overall model significance was assessed by partial 
likelihood ratio tests comparing each of the fitted models to the univariable model. The final 
model was selected by entering all the covariates from earlier models and using a backward 
elimination strategy.222, 223  Variables were selected for elimination one at a time based on 
univariate Wald tests. After each variable was removed from the model, the partial likelihood 
ratio test was calculated comparing the nested models. Removed variables remained out of the 
models if they made no significant contribution to the model. Likelihood ratio tests were used to 
evaluate the significance of potential interactions by comparing the model including the 
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 interaction term to the main effects model. Analyses were repeated among subgroups defined 
by age (<75 and ≥75 years) and BMI (<30 and ≥30 kg/m2). Due to small numbers, 25(OH)D was 
investigated as a continuous variable in subgroup analyses. For the final model, probability 
values < 0.05 were considered statistically significant. All tests were two-tailed.  
Power was calculated a priori using previously reported SOF data (serum 25(OH)D 
mean (SD) = 25.8 (10.7) ng/ml)224 with PASS 2005 software (NCSS, Kaysville, Utah). A two-
sided two-sample t-test with equal variance, an alpha level of 0.05, 175 cases, and a 350 
member subcohort, provides 80% power to detect a mean difference of 2.78 ng/ml (Cohen’s d = 
0.26) in the cases compared to the subcohort. Data descriptions, including graphical 
presentations, were carried out in STATA version 10. Cox proportional hazards modeling was 
performed using SAS software release 9.1.3 (SAS Institute Inc., Cary, NC). 
4.4 RESULTS 
This case-cohort study of postmenopausal women within the Study of Osteoporotic Fractures 
was comprised of 170 incident ER+ breast cancer cases and 332 non-cases. The mean time 
between baseline blood draw and breast cancer diagnosis was 6.0 years. Table 4 presents the 
characteristics, including socio-demographic variables and established breast cancer risk 
factors of the study population at baseline. The mean age of cases and non-cases at baseline 
are 70.4 and 71.2 years, respectively. Compared to non-cases, cases were heavier (weight 
p<0.01; BMI p=0.02), and taller (p=0.03). Cases also had slightly higher bone mineral density 
(p=0.06), and were less likely to have ever smoked (p=0.06), although these differences were of 
borderline statistical significance.  
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 Median serum concentrations of 25(OH)D were 27.3 ng/ml and 27.5 ng/ml among cases 
and non-cases, respectively (p=0.51). Table 5 gives details of the median 25(OH)D levels by 
important study characteristics. Median 25(OH)D levels were highest among current vitamin D 
supplement users (31.1 ng/ml) compared to past (23.2 ng/ml) and never (24.5 ng/ml) users 
(p<0.01) and among women with a normal BMI (28.6 ng/ml) compared to those who were 
overweight (25.9 ng/ml) or obese (27.9 ng/ml) (p=0.03). Measurements were highest when 
taken during the summer months (28.9 ng/ml), and lowest during the spring (25.7 ng/ml); this 
difference was of borderline statistical significance (p=0.06). There was no significant difference 
in median 25(OH)D concentration by age group (p=0.69). 
Table 6 shows the multivariable adjusted regression results for the association between 
serum level of 25(OH)D and incident breast cancer. In the simple analysis (model 1) of serum 
25(OH)D categorized at clinically relevant cutpoints, which adjusted for age (as timescale), clinic 
site, and season of blood draw, there was no association with breast cancer (HR 1.13 for < 20 
ng/ml, 95%CI 0.65-1.96; reference level ≥ 30 ng/ml). In model 2, the addition of BMD, weight, 
and smoking status slightly increased the risk estimate from 13% to 22% although it was not 
significant (HR 1.22 for < 20 ng/ml, 95%CI 0.66-2.24; reference level ≥ 30 ng/ml). Adjustment 
for a priori breast cancer risk factors in model 3 attenuated the risk estimate (HR 1.06 for < 20 
ng/ml, 95%CI 0.54-2.10; reference level ≥ 30 ng/ml). In the main analysis (model 4), the lack of 
association between serum concentration of 25(OH)D and risk of postmenopausal ER+ breast 
cancer persisted. Compared with the highest category (≥ 30 ng/ml), the HR’s (95%CI) for lower 
serum concentrations (20-30 and < 20 ng/ml) were 0.94 (0.61-1.46) and 1.15 (0.63-2.12), 
respectively (p=0.68). A test of linear trend was not significant (ptrend=0.69). No significant 
association was found with serum 25(OH)D modeled as a continuous variable (RR 1.01 per 1 
SD decrease, 95%CI 0.80-1.26).  
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 An examination of the shape of the risk function using cubic splines, displayed in Figure 
4, showed no significant non-linearity (p=0.65). 
Results of the subgroup analyses addressing the secondary aims are presented in 
Table 7. In multivariable models with 25(OH)D modeled as a continuous variable, no 
association between 25(OH)D and breast cancer was observed among women less than 75 
years of age (RR 1.09 per 1 SD decrease, 95%CI 0.84-1.41). However, among women 75 years 
and older, a significant decrease in the risk of breast cancer was found with lower levels of 
25(OH)D (RR 0.50 per 1 SD decrease, 95%CI 0.27-0.92). The interaction between age and 
25(OH)D was not significant (pinteraction=0.43). There was no difference in the relationship 
between 25(OHD) and breast cancer risk by obesity, RR (95%CI) of breast cancer per 1 SD 
decrease in 25(OH)D was 1.00 (0.79-1.27) and 0.79 (0.27-2.29) for non-obese (BMI < 30 kg/m2) 
and obese (BMI ≥ 30 kg/m2) women, respectively (pinteraction=0.27). 
4.5 DISCUSSION 
This prospective, case cohort study of 502 postmenopausal women from the Study of 
Osteoporotic Fractures, showed little evidence of an association between serum 25(OH)D and 
ER+ breast cancer. A positive relationship was noted among women greater than 75 years of 
age. The association between serum 25(OH)D and ER+ breast cancer did not seem to differ by 
obesity. 
Previous studies reporting on the association between 25(OH)D concentration and 
postmenopausal breast cancer show disparate results; two have found an inverse association, 
while the third shows no association.130-132  Most recently, a case-cohort study from the 
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial found no association overall 
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 among women 55-74 years (RR 1.04 for < 18.3 vs. ≥ 33.7 ng/ml, 95%CI 0.75-1.45, ptrend=0.81) 
or when limited to women aged 60 and older (results not reported).130  The Nurse’s Health Study 
reported a modest but non-significant decreased risk of breast cancer in women 60 years and 
older (RR 0.57 for ≥ 41.7 vs. ≤ 22.0 ng/ml, 95%CI 0.31-1.04, ptrend=0.03).131  In addition, they 
evaluated the relationship by estrogen and progesterone receptor status, and while they 
reported an inverse association for ER-/PR- (ptrend=0.08) but not for other subtypes (ER+/PR+ 
ptrend=0.30; ER+/PR- ptrend=0.33), statistical significance was not reached. Moreover, these later 
findings were for a combined pre- and post-menopausal population. These two findings appear 
to be contradictory given the observed associations were greater among older women who are 
more likely to have ER+ breast cancer, and for ER- cancers which are more likely to occur 
among younger women. In contrast, a single case-control study, reporting a strong inverse 
association among 1394 postmenopausal cases (OR=0.31 for ≥ 30 vs. < 12  ng/ml, 95%CI=0.2-
0.4), reported no effect modification by ER status.132  These findings are of limited relevance to 
the development of breast cancer as blood samples were collected after the diagnosis of breast 
cancer. Furthermore, as noted by Abbas et al., dietary and behavioral changes, as well as 
cancer therapy have the potential to affect circulating levels of 25(OH)D following a diagnosis.132 
Our findings are noteworthy as they add to the small body of epidemiologic data 
concerning circulating 25(OH)D and breast cancer. The overall lack of association of serum 
25(OH)D and ER+ breast cancer is consistent with the limited information currently known 
regarding the association with different tumor subtypes. One potential explanation is that 
circulating 25(OH)D is not an adequate measure of localized levels in the breast. It is also 
possible, due to the estrogen sensitivity of ER+ tumors, that estrogen plays a greater role in the 
development of breast cancer than the capacity of vitamin D to act as a preventive factor. More 
than 18% of the women in this study reported current estrogen use at baseline. However, 
adding exogenous estrogen use (current/past/never) to our multivariable models had little effect 
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 on our 25(OH)D estimates. The body’s reaction to vitamin D also may deteriorate with old age. 
The lack of an association may reflect either a decline in the interaction between 1,25(OH)2D 
and VDRs in breast tissue, or diminished VDR expression. A study of muscle tissue found a 
significant decrease in VDR expression with increasing age (r=0.5, p=0.004) that was not 
correlated to either circulating 25(OH)D or 1,25(OH)2D levels.225  Furthermore, reports of tumors 
developing mechanisms to negate the anti-proliferative effects of 1,25(OH)2D at the cellular 
level, such as enhancing expression of 24-OHase, the enzyme responsible for destroying 
1,25(OH)2D, have been made.226   
Body fat has been shown to negatively impact vitamin D levels; obese individuals have 
lower vitamin D bioavailability,227 and 25(OH)D concentration is inversely associated with 
adiposity.228  While we did see a significant difference in median 25(OH)D level by BMI 
category, the risk of ER+ breast cancer according to 25(OH)D level was not different for obese 
and non-obese women in this study. It has been hypothesized that because older women have 
a lower lean muscle to fat ratio for a given weight compared to younger women, BMI may not be 
an accurate measure of obesity among these women.51 Nevertheless, obesity may be an 
important mediating factor in the association between vitamin D and breast cancer risk. 
 Our positive finding of a 50% reduced risk with lower 25(OH)D concentration among 
women 75 years of age and greater has never been reported. We do not interpret this to mean 
that higher levels of 25(OH)D lead to the development of breast cancer, but rather that there 
may be age related changes in the interaction of vitamin D and breast tissue. This result may 
have occurred by chance and further confirmation of this finding is needed. 
 While there is no established optimal serum 25(OH)D concentration, it is accepted to be 
at least 30 ng/ml which causes a plateau in serum parathyroid hormone level.229  
Recommended levels for cancer prevention are even higher (36-48 ng/ml).100  There has only 
been one randomized controlled trial (RCT) of vitamin D supplementation and breast cancer 
59 
 
 risk. The findings of the WHI showed no association with incident breast cancer risk.126  
However the dose of vitamin D (400 IU / day) administered in the WHI is not thought to have 
been high enough to adequately raise vitamin D levels. A RCT of  overall incident cancer found 
a statistically significant reduced risk of cancer with combined daily calcium (1500 mg) and 
vitamin D (1100 IU) supplementation among postmenopausal women over age 55.127   
Strengths of this study include its prospective case-cohort design from the large and 
long-standing population-based SOF cohort. We utilized pre-diagnostic serum samples and 
quantitatively measured 25(OH)D with the reliable Diasorin RIA assay. The 25(OH)D metabolite 
integrates all sources of vitamin D from diet, supplement, and sunlight making it a clinically 
relevant indicator of vitamin D status.  
Limitations of this study include our reliance upon a single measure of 25(OH)D, which 
may not reflect long-term status. While our measure of total 25(OH)D was not able to distinguish 
between 25(OH)D2 and 25(OH)D3, this is not of particular concern as both metabolites have 
been shown to have a similar extremely high affinity in our assay (100% cross-reactivity).129  
Furthermore, we lacked a measure of the biologically active vitamin D metabolite 1,25(OH)2D. 
Because our study is comprised of older Caucasian women, our results may not be 
generalizable to other populations. 
In conclusion, the findings of this study do not support a protective effect of 25(OH)D on 
ER+ breast cancer risk in postmenopausal women 65 years of age and older. However, the 
positive association among women 75 years and greater is suggestive of a change in the 
interaction of vitamin D in the breast. Further investigations of the role of vitamin D on breast 
cancer development among elderly women are warranted. In particular, it will be important to 
better define the factors influencing 25(OH)D levels in this vulnerable age group. Future studies 
should also include adequate numbers of women with ER- breast cancer. 
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 4.6 TABLES AND FIGURES 
Table 4. Baseline characteristics of study population, Study of Osteoporotic Fractures 
 Breast Cancer Cases Subcohort Non-Cases  
  (n=170) (n=332) 
Characteristic 
61 
N % N % p-value* 
0.08† Age, y, mean(SD) 70.44 (4.54) 71.21 (4.70) 
Clinic Site     0.98# 
A 42 24.71 83 25.00  
B 49 28.82 93 28.01  
C 40 23.53 83 25.00  
D 39 22.94 73 21.99  
Education     0.48# 
< High School 31 18.24 73 21.99  
High School 70 41.18 140 42.17  
> High School 69 40.59 119 35.84  
Distal Radius BMD, g/cm2, mean(SD) 0.38 (0.09) 0.37 (0.09) 0.06 
Body Weight, kg, median(IQR) 69.9 (61.1-78.2) 65.5 (59.3-73.6) <0.01‡ 
BMI, kg/m2, median(IQR) 25.8 (23.1-29.2) 24.9 (22.7-27.6) 0.02‡ 
BMI     0.08# 
< 25 78 44.24 164 51.57  
25-29 58 35.15 112 35.22  
> 30 34 20.61 42 13.21  
0.70† Waist/Hip Ratio, mean(SD) 0.81 (0.07) 0.81 (0.06) 
0.03† Height at age 25 y, cm, mean(SD)  163.52 (5.46) 162.39 (5.66) 
0.87# Age at Menarche, y     
< 11 24 15.19 43 14.01  
12-13 85 53.80 162 52.77  
> 14 49 31.01 102 33.22  
Nulliparous 25 14.71 66 19.88 0.15# 
0.29# Number of Live Births     
Never pregnant 25 14.71 66 19.88  
0 4 2.35 6 1.81  
1-2 75 44.12 121 36.45  
3-4 45 26.47 105 31.63  
5+ 21 12.35 34 10.24  
0.76# Age at First Birth, y     
< 20 30 17.65 52 15.66  
> 20 104 61.18 198 59.64  
Never gave birth 27 15.88 65 19.58  
Unknown 9 5.29 17 5.12  
 
 Table 4. continued 
 Breast Cancer Cases Subcohort Non-Cases 
  (n=170) (n=332) 
Characteristic 
62 
N % N % p-value* 
0.79# Ever Breastfed 99 68.28 185 69.55 
0.32# Age at Menopause, y     
< 40 10 5.88 27 8.13  
41-45 30 17.65 46 13.86  
46-50 45 26.47 110 33.13  
> 51 55 32.35 89 26.81  
Unknown 30 17.65 60 18.07  
Surgical Menopause 28 16.77 40 12.54 0.20# 
0.31# Walks for Exercise 84 49.41 180 54.22 
0.59# Alcohol, drinks/week   
None 74 43.53 141 42. 47  
≤1 63 37.06 129 38.86  
2-7 19 11.18 44 13.25  
8+ 14 8.24 18 5.42  
Smoking     0.06# 
Never 119 70.00 202 61.03  
Past 36 21.18 103 31.12  
Current 15 8.82 26 7.85  
0.36† Dietary Calcium Intake, mg/d, mean(SD) 726.72 (428.62) 765.81 (458.71) 
0.59† Supplemental Calcium Intake, mg/d, 
mean(SD) 
388.58 (555.43) 360.67 (524.62) 
0.86† Total Calcium Intake, mg/d, mean(SD) 1130.30 (708.80) 1118.60 (683.87) 
0.98# Current Calcium Supplement Use 71 41.76 137 41.64 
History of Osteoporosis 23 13.86 43 13.03 0.80# 
Oral Estrogen Use     0.78# 
Never  86 51.05 171 52.62  
Past 53 31.74 94 28.92  
Current 28 16.77 60 18.46  
0.49# Any Current Estrogen Use 34 20.61 75 23.36 
Benign Breast Disease 35 22.01 51 16.24 0.12# 
Family History of Breast Cancer 
22 13.41 42 13.13 0.93# 
 
*Reported p-values are from tests of significance comparing the combined case-groups (n=170) and the non-case 
subcohort (n=332) 
†T-test 
‡Wilcoxon two sample rank-sum test 
#Chi-square test 
Abbreviations used: BMI, body mass index; IQR, interquartile range; SD, standard deviation 
 
 Table 5. Median 25-hydroxyvitamin D level by disease status and important study characteristics, 
Study of Osteoporotic Fractures 
 25(OH)D, ng/ml  
 Median (IQR) p-value 
    
   Group 
Cases, n=170  27.26 21.6-32.4 0.51† Non-Cases, n=332 27.49 22.7-33.2 
    
Age*    
65-69, n=147 28.04 23.4-33.6 
70-74, n=105 27.13 22.0-32.5 0.69‡ 75-79, n=58 26.46 21.6-34.2 
80+, n=22 29.67 20.7-31.6 
    
Season*    
Winter, n=64  26.50 20.9-35.9 
Spring, n=79  25.74 21.5-31.3 0.06‡ Summer, n=106 28.92 24.5-33.4 
Fall, n=83 27.56 22.8-34.6 
    
Vitamin D Supplement Use*    
Current, n=144 31.10 26.3-35.9 <0.01‡ Past, n=35 23.21 20.2-31.5 
Never, n=147 24.51 20.7-29.7  
    
BMI*, kg/m2    
< 25, n=164 28.59 23.6-35.3  
0.03‡ 25-29, n=112 25.94 21.7-32.2 
>
63 
 30, n=42 27.91 21.5-31.4  
    
 
*Comparison is among non-cases only 
†Wilcoxon two-sample rank-sum test 
‡Kruskal-Wallis test 
Abbreviations used: IQR, interquartile range 
 
 Table 6.  Association of serum 25(OH)D level and ER+ breast cancer, Study of Osteoporotic 
Fractures 
 Model 1 Model 2  
N=487 
Model 3 Model 4 
 N=502 N=437 N=479 
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 HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Categorical 25(OH)D ng/ml     
<20 1.13 (0.65-1.96) 1.22 (0.66-2.24) 1.06 (0.54-2.10) 1.15 (0.63-2.12) 
≥20 to <30 0.94 (0.62-1.43) 0.90 (0.59-1.38) 0.95 (0.59-1.51) 0.94 (0.61-1.46) 
≥30 1.00 1.00 1.00 1.00 
p-value 0.73 0.42 0.88 0.68 
Continuous 25(OH)D     
RR*  1.01 (0.83-1.23) 1.01 (0.81-1.27) 0.96 (0.75-1.23) 1.01 (0.80-1.26) 
p-value 0.96 0.91 0.75 0.95 
Clinic Site     
A 1.00 1.00 1.00 1.00 
B 1.16 (0.69-1.96) 1.10 (0.63-1.93) 1.09 (0.59-2.02) 1.02 (0.58-1.80) 
C 1.04 (0.61-1.79) 1.05 (0.60-1.83) 1.02 (0.53-1.94) 1.03 (0.59-1.80) 
D 1.14 (0.67-1.95) 1.09 (0.62-1.90) 0.96 (0.50-1.83) 1.07 (0.61-1.89) 
Season     
Winter 0.86 (0.51-1.46) 0.72 (0.41-1.26) 0.76 (0.38-1.53) 0.76 (0.43-1.35) 
Spring 0.99 (0.60-1.63) 0.98 (0.58-1.65) 1.16 (0.62-2.15) 1.01 (0.60-1.70) 
Summer 0.54 (0.33-0.90) 0.51 (0.30-0.85) 0.58 (0.33-1.04) 0.50 (0.29-0.84) 
Fall 1.00 1.00 1.00 1.00 
Distal Radius BMD, g/cm2 ----- 1.44 (0.13-15.45) ----- ----- 
Body Weight, kg ----- 1.03 (1.01-1.05) 1.03 (1.01-1.05) 1.03 (1.01-1.04) 
Smoking     
Never ----- 1.00 ----- 1.00 
Past ----- 0.59 (0.37-0.93) ----- 0.59 (0.37-0.93) 
Current ----- 0.99 (0.49-1.99) ----- 1.06 (0.52-2.18) 
Oral ET Use     
Never  ----- ----- 1.00 1.00 
Past ----- ----- 1.16 (0.70-1.92) 1.06 (0.66-1.70) 
Current ----- ----- 0.96 (0.48-1.93) 1.13 (0.64-2.00) 
Benign Breast Disease ----- ----- 1.45 (0.76-2.74) ----- 
Family History of Breast Cancer ----- ----- 0.97 (0.50-1.85) ----- 
Age at Menarche, y     
< 11 ----- ----- 1.00 ----- 
12-13 ----- ----- 1.18 (0.64-2.18) ----- 
> 14 ----- ----- 1.03 (0.50-2.10) ----- 
Number of Live Births     
No term pregnancy ----- ----- 0.83 (0.16-4.13) ----- 
1-2 ----- ----- 1.00 (0.47-2.14) ----- 
3-4 ----- ----- 0.66 (0.40-1.09) ----- 
5+ ----- ----- 1.00 ----- 
 
 Table 6. continued 
 Model 1 Model 2  
N=487 
Model 3 Model 4 
 N=502 N=437 N=473 
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 HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Age at Menopause, y     
       ≤40 ----- ----- 1.00 ----- 
       41-50 ----- ----- 1.29 (0.73-2.29) ----- 
       ≥51 ----- ----- 1.39 (0.77-2.49) ----- 
Walks for Exercise ----- ----- 0.83 (0.53-1.29) ----- 
Current Alcohol Use ----- ----- 0.76 (0.48-1.21) ----- 
 
*Relative risk for a 1 SD (9.2 ng/ml) decrease in serum 25(OH)D; continuous 25(OH)D modeled separately from 
categorical 25(OH)D 
Models 1-4: All models are adjusted for age (as timescale) season of blood draw, and clinic site 
Model 2: Adjusted for baseline characteristics found to be significantly different between cases and the subcohort in 
univariate analyses at p<0.1 
Model 3: Adjusted for a priori established breast cancer risk factors 
Model 4: Adjusted for ET use in addition to covariates in Models 2 and 3 that remained statistically significant at 
p<0.1 via manual backwards elimination strategy 
Abbreviations used: CI, confidence interval; HR, hazard ratio; RR, relative risk 
 
 
 
 
 
Table 7. Estimated relative risk of serum 25(OH)D level and ER+ breast cancer according to risk 
subgroup, Study of Osteoporotic Fractures 
Relative Risk of 
Breast Cancer Risk Subgroup Cases / P value Non-cases RR (95%CI)* 
  0.43† Age   
< 75 years 135 / 234 1.09 (0.84-1.41) 0.52 
≥75 years 27 / 76 0.50 (0.27-0.92) 0.03 
  0.27† BMI   
< 30 kg/m2 128 / 268 1.00 (0.79-1.27) 0.97 
≥ 30 kg/m2 34 / 42 0.79 (0.27-2.29) 0.66 
 
*Relative risk for a 1 SD (9.2 ng/ml) decrease in serum 25(OH)D; adjusted for age (as 
timescale), clinic site, season of blood draw, BMI, smoking history, and oral ET use 
†P-value for interaction between subgroup variable and 25(OH)D   
Abbreviations used: BMI, body mass index; CI, confidence interval; RR, relative risk 
 
  
 
 
 
Figure 4. Cubic spline transformation of serum 25(OH)D concentration 
Knot placement indicated by horizontal lines at 15, 20 and 30 ng/ml. Outer bands represent 95% 
confidence intervals. Plinearity=0.65. 
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 5.1 ABSTRACT 
Although epidemiologic evidence suggests that vitamin D may reduce the incidence of breast 
cancer, reports in the literature have been inconsistent, particularly in regard to postmenopausal 
women. The possibility that age related tissue resistance to the active vitamin D metabolite 
(1,25-dihydroxyvitamin D) may interrupt the protective mechanism by which vitamin D is thought 
to prevent breast cancer has not been investigated. In this prospective study, we examined the 
association between fractional calcium absorption (FCA), utilized as a marker of tissue 
resistance, and breast cancer risk in the Study of Osteoporotic Fractures (SOF), a cohort of 
9,704 Caucasian, postmenopausal women aged 65 and older. Of these, the rate of FCA was 
obtained by single isotope method for 5035 women, 257 of whom later developed an incident 
case of breast cancer. A Cox proportional hazards analysis was performed to compute hazard 
ratios (HRs) and 95% confidence intervals (95%CIs). Subgroup analyses by calcium intake, 
vitamin D supplementation, age, and estrogen therapy (ET) were also performed. Mean time 
between FCA measure and breast cancer diagnosis was 9.6 years. The mean FCA rate was 
higher among cases compared to non-cases (38.7% vs. 37.6%), although of borderline 
significance (p=0.05). In multivariable models, increasing rates of FCA were associated with a 
slightly higher risk of invasive breast cancer (HR 1.15 per 1 SD increase, 95%CI 1.00-1.32, 
p=0.05). Compared with the lowest quartile of FCA (≤ 0.314), women with higher FCA (0.315-
0.372, 0.373-0.434, ≥ 0.435) had relative risks (HR, 95%CI) of 1.54 (1.01-2.34), 1.50 (0.99-
2.29), and 1.47 (0.96-2.26), respectively (ptrend=0.14). In a subgroup analyses with FCA 
dichotomized at the lowest quartile (0.314), a stronger positive relationship was noted among 
women with low (HR 2.34 ≤ 525 mg/d, 95%CI 1.21-4.52) but not high (HR 1.12 > 525 mg/d, 
95%CI 0.71-1.76) dietary calcium intake (pinteraction=0.06). The findings of this prospective study 
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 of postmenopausal women are supportive of a modestly increased risk of breast cancer with 
higher FCA rates particularly among those who have low calcium intake. 
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 5.2 INTRODUCTION  
The role of vitamin D in breast cancer etiology has been proposed through ecologic,112, 113 
dietary intake,119, 121-125, 127 and analytic studies.130-134  Both normal and cancerous mammary 
cells have the ability to convert circulating 25-hydroxyvitamin D [25(OH)D] into the biologically 
active form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D].95, 107  Breast cells also contain 
the vitamin D receptor (VDR) which is activated through interaction with 1,25(OH)2D to play a 
direct role in growth regulation of both normal mammary gland and breast cancer cells by 
inducing cell differentiation and apoptosis and inhibiting cellular proliferation.105, 109  A possible 
mechanism for the malignant transformation of breast cells is through insufficient 25(OH)D 
levels, which limits the synthesis of 1,25(OH)2D and prevents activation of the VDR to regulate 
the cell cycle.98  Alternatively, decreased sensitivity of breast tissue to 1,25(OH)2D may also 
serve to limit VDR mediated cell cycle regulation.  
Fractional calcium absorption, a measure of intestinal calcium absorption, varies widely 
from person to person. Among postmenopausal women, FCA values have been reported to 
range from 0.07 to 0.68 with an average of 0.27 ± 0.10 (SD).140  It is well established that 
intestinal calcium absorption declines with increasing age.137, 143, 145, 151, 160, 161  By far, the most 
significant factor affecting intestinal calcium absorption is its hormonal regulator, 1,25(OH)2D.142-
145  Approximately 20% of the variation in calcium absorption between individuals can be 
explained by circulating 1,25(OH)2D.142  Some studies,142, 145, 146 but not all,147-153 have reported 
decreased levels of serum 1,25(OH)2D with age. 
Intestinal calcium absorption has been touted as a marker of tissue responsiveness to 
vitamin D, and aging associated with reduced sensitivity to 1,25(OH)2D.167  The evidence 
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 supporting this claim is of varying strength. One study demonstrated unchanging calcium 
absorption with increasing age despite higher levels of 1,25(OH)2D, suggestive of intestinal 
resistance to 1,25(OH)2D with aging.150  Similarly, reduced calcium absorption was reported 
among non-estrogen users over age 75, despite unchanging 1,25(OH)2D or 25(OH)D levels.143  
Perhaps the most compelling findings are from a study by Pattanaungkul et al. which clearly 
shows that in young women (mean 29 years) FCA increases with increasing serum 1,25(OH)2D 
concentration, while the increase in FCA among elderly women (mean 73 years) is significantly 
diminished with increasing serum 1,25(OH)2D concentration (p=0.03).168 
Based upon the current knowledge, it is conceivable that other vitamin D sensitive 
tissues, such as breast tissue, may also have diminished response to vitamin D with aging. 
Decreased ability to absorb calcium with age, indicative of reduced gut tissue responsiveness to 
vitamin D, may be representative of other tissue’s responsiveness to vitamin D. In this 
prospective cohort study, we investigated the relationship between FCA, utilized as a marker of 
tissue responsiveness to vitamin D, and breast cancer among postmenopausal women. 
Specifically, we tested the hypothesis that low FCA will be associated with an increased risk of 
invasive and estrogen receptor positive (ER+) breast cancer. We also tested whether this 
relationship differed by calcium intake, vitamin D supplementation, and hormone therapy as 
secondary aims. The association between FCA and breast cancer has never been studied. 
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 5.3 METHODS 
5.3.1 Study Population 
The Study of Osteoporotic Fractures is a longitudinal cohort of 9,704 community-dwelling, 
Caucasian, postmenopausal women aged 65 and over who were recruited at 4 US clinical 
centers between 1986 and 1988. Women with a history of bilateral hip replacements and those 
who were unable to walk unassisted were excluded.210  At the baseline examination, women 
provided informed consent and risk factor and health measures were collected through physical 
measurements, questionnaires, and functional assessments. 
Fractional calcium absorption was assessed at the fourth clinic visit (V4) between 1992 
and 1994. All SOF participants with a V4 fractional calcium absorption measure (n=5452) were 
eligible. Individuals reporting a history of breast cancer at enrollment (n=240) and those with an 
incident breast cancer diagnosed prior to V4 (n=116) were excluded from this analysis. 
Additionally, women with missing outcome data (n=71) were excluded. Figure 5 details the 
selection process for the analysis population. Follow-up continued through December 2006 at 
which time the women were censored who did not develop breast cancer, experience death, or 
were not lost to follow-up. This analysis includes 257 cases and 4778 non-cases. 
72 
 
  
 
 
 
 
 
 
 
    
 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
   257 Cases 4778 Noncases 
FCA Measure 
5,452 
878 Excluded 
         85 Ineligible* 
       793 Missing† FCA 
1292 Excluded 
         142 Terminated 
         933 Died 
         213 Postcard only 
 4 Lost to follow-up 
2082 Excluded 
           488 Home visit 
         1309 Questionnaire only 
           285 Minimal data 
Total in SOF Cohort 
9,704 
(1986-1988) 
V4 Clinical Exam 
6,330 
Total in Analysis 
5035 
417 Excluded 
       240 Prior history of breast cancer at baseline 
       116 Incident breast cancer at or before V4 
         71 Missing‡ breast cancer info at follow-up  
Eligible for Clinic V4 
8,412 
(1992-1994) 
Figure 5. Cascade of analysis population determination, Study of Osteoporotic Fractures  
*Women were deemed ineligible for the FCA test if they reported experiencing nausea, vomiting or
diarrhea in the 48 hours preceding the exam. †Missing FCA includes those who refused testing or 
had incomplete tests. ‡Missing values coded as refused to answer (n=54), unable to answer (n=6), 
never had a period (n=11). 
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 5.3.2 Fractional Calcium Absorption Measurement 
Details of the FCA assessment have been published previously.166  FCA testing was completed 
in the morning after a 5-hour fast. Participants were instructed not to take any calcium 
supplements for 12 hours before testing. Midway through consumption of a standardized light 
test meal, participants ingested a mixture of 50 grams of radio-labeled apple juice (containing 63 
mg of 45Ca) and 120 grams of unlabeled apple juice (Speas Farm, Sundor Brands, Mt. Dora, 
Florida) for a total calcium load of 215 mg. The mixture was prepared on site at each of the four 
clinics with labeled 45Ca from the Osteoporosis Research Center at Creighton University in 
Omaha Nebraska. Fractional 45Ca absorption was estimated from the appearance of 45Ca in the 
blood. Blood was drawn into a serum separator tube exactly 3 hours after ingestion of the tracer 
and was allowed to clot at room temperature. Within 2 hours of collection, serum was separated 
and frozen at -700C until analysis. Frozen serum samples were later shipped on dry ice by 
overnight delivery to Creighton University, where fractional calcium absorption was estimated by 
a single isotope method.230, 231  
5.3.3 Covariate Information 
At the baseline (V1) and fourth clinic visits (V4), participants completed a questionnaire and 
were interviewed. Demographic (age, education), reproductive history (menarche age, parity, 
age at first birth, number of live births, breastfeeding), height at age 25, menopausal status 
(menopause age, surgical vs. natural menopause), and breast cancer risk factor (benign breast 
disease, family history of breast cancer) data were collected at the baseline examination. At the 
V4 examination, updated smoking status, alcohol use, physical activity, and ET data were 
collected. Body weight was measured using a balance-beam scale. Weight change was 
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 calculated by subtracting weight at V1 from V4. Body mass index (BMI) was calculated by 
dividing the V4 weight by the square of height at age 25 years. Bone mineral density (g/cm2) of 
the proximal femur was measured using dual-energy x-ray absorptiometry (QDR 1000, Hologic, 
Waltham, Massachusetts).210, 213  In addition, they were asked to bring current medications 
including vitamins and supplements and the total daily dose of calcium and vitamin D were 
recorded. Current supplemental vitamin D use was defined as taking vitamin D or a multivitamin 
containing vitamin D at least once per week. Calcium supplementation was determined by 
asking questions about dose and frequency of multivitamin use, specific vitamin and mineral 
supplements, and antacids containing calcium. Dietary calcium intake was estimated by using a 
validated 60-item block semi-quantitative food-frequency questionnaire developed from the 
Second National Health and Nutrition Survey (NHANES II).214, 215  Total calcium intake was 
calculated by summing dietary calcium intake (mg/d) and daily dose of calcium supplements 
(mg/d). Month of FCA measure was grouped into seasons of winter (December-February), 
spring (March-May), summer (June-August), and fall (September-November). Variables were 
categorized based on common cutpoints (e.g. BMI) or the original response categories 
collapsed to prevent small cell counts (e.g. age at first birth). Continuous variables were 
additionally dichotomized at their median and/or divided into quartiles for analytic purposes. 
5.3.4 Incident Breast Cancer Ascertainment 
Follow-up occurred every four months by either postcard or telephone (98% complete) in 
addition to clinic visits approximately every 2 years. Breast cancer outcomes were originally 
ascertained through self-report or death certificate review and were adjudicated by physicians 
locally and centrally at the San Francisco Coordinating Center. Medical records and pathology 
reports were used to record information on date of breast cancer diagnosis, stage at diagnosis, 
and estrogen- and progesterone-receptor status.184 
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 5.3.5 Statistical Analysis 
As part of the preliminary data analysis the distribution of baseline characteristics (measured at 
V1 or V4) were compared by disease status (cases vs. non-cases) using t-tests for continuous 
measures and chi-square tests for categorical data. Mean FCA also was compared by disease 
status (case/non-case), age (<75/≥75 years), season of blood draw (winter/spring/summer/fall), 
vitamin D supplement use (current/not current), total calcium intake (<775/≥775 mg/d), oral 
estrogen use (current/not current), height at age 25 (<163/≥163 cm), body weight (<65/≥65 kg), 
BMI (<30/≥30 kg/m2), alcohol use (<1/≥1 drink/week), and smoking status (current/not current) 
using either t-tests or ANOVA.  
The Kaplan-Meier method for survival analysis was used to compare time to breast 
cancer diagnosis by quartile of FCA. A log-rank test was used to assess differences by FCA 
quartile. Follow-up time for each woman was calculated in days from V4 to breast cancer 
diagnosis, death, loss to follow-up, or censoring. 
The main analysis estimated hazard ratios and 95% confidence intervals for the 
association between FCA and the risk of breast cancer using Cox proportional hazard 
regression models with age as the underlying time scale.217-219  Age at entry in days, was 
calculated by multiplying age at V4 (time of the FCA measure) by 365.25. Age at exit from the 
study was calculated by adding follow-up time in days from V4 to study end (i.e. time to breast 
cancer diagnosis, death, loss to follow-up or censoring) to entry age. Levels of FCA were 
entered as a continuous variable to estimate the HR of breast cancer per one standard 
deviation (SD) increase in FCA. FCA levels were also assessed as quartiles based on the 
distribution of FCA in the entire cohort and using the lowest category as the reference. All 
models were adjusted for SOF clinic site. The potential confounders described above were 
evaluated for inclusion in the multivariable adjusted model based on their significance (p≤0.1) in 
the univariate and bivariate analyses. In situations where variables are correlated, e.g. various 
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 measures of body size, covariates were chosen based on statistical association, scientific 
knowledge, and/or variable distribution. Dummy variables were created for categorical variables 
as appropriate. Variables were selected for elimination one at a time using a backward 
elimination strategy based on individual Wald tests.222, 223  After each variable was removed 
from the model, the partial likelihood ratio test was calculated comparing the nested models. 
Removed variables remained out of the models if no significant contribution to the model was 
determined (p≥0.1). Interactions were evaluated using likelihood ratio tests that compared the 
model with the interaction term to the main effects model (p≥0.05).   
The potential for non-linear effects was investigated using cubic splines. RCS (restricted 
cubic splines), a SAS macro, was used to fit the cubic splines.221  Knot placement was set at the 
FCA quartile cut-points. All breast cancers including in situ and invasive only breast cancers 
were analyzed separately. Although the inclusion of in situ did not substantially impact the 
results, regression results for invasive only and ER+ cancers are presented. The final 
multivariable model was assessed for a linear contrast with FCA quartile 1 vs. quartiles 2-4. 
Analyses were also repeated among subgroups defined by age, dietary calcium intake, use of 
calcium supplements, total calcium intake, vitamin D supplementation (current/not current), and 
oral estrogen use (current/not current). FCA was split at quartile 1 vs. quartiles 2-4 for subgroup 
analyses; continuous variables were dichotomized at the median value. Additionally, in 
response to the recent WHI report of an interaction between calcium and vitamin D 
supplementation and hormone therapy (HT),232 FCA was investigated by total calcium intake 
and oral estrogen use simultaneously. Likelihood ratio tests were used to evaluate possible 
interactions between the subgroup variable and FCA by comparing a multivariable model with 
and without the interaction term expressed as the product of the variable and dichotomous FCA. 
For the final models, probability values <0.05 were considered statistically significant. All tests 
were two-tailed. Schoenfeld residuals were used to test the proportional hazards assumption. 
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  Power was calculated a priori using previously reported SOF data and PASS 2005 
software (NCSS, Kaysville, Utah).  With a mean fractional calcium absorption level of 0.38 and a 
standard deviation of 0.09,166 we have a minimum of 80% power to detect a mean difference of 
0.02. A two-sided two-sample t-test was conducted using an alpha level of 0.05. Calculations 
were based on 250 cases and 4775 controls. Data descriptions, including graphical 
presentations, were carried out in STATA version 10. Kaplan-Meier survival analysis and Cox 
proportional hazards modeling was performed using SAS software release 9.1.3 (SAS Institute 
Inc., Cary, NC). 
5.4 RESULTS 
This prospective cohort study investigated the relationship between fractional calcium 
absorption, utilized as a marker of tissue responsiveness to vitamin D, and breast cancer 
among 5035 postmenopausal women in the Study of Osteoporotic Fractures. Table 8 presents 
the characteristics, including socio-demographic variables and established breast cancer risk 
factors of the analysis population at baseline or V4.  
The mean age of cases and non-cases at V4 are 75.5 and 76.5 years, respectively. 
Compared to non-cases, cases weighed more (p<0.001), had higher BMI (p=0.004), had higher 
hip BMD (p=<0.0001), were older at menopause (p=0.007), took more supplemental calcium 
(p=0.03), had a greater total daily calcium intake (p=0.02), took ET more frequently (25.7% vs. 
18.6%, p=0.005), and were more likely to have a positive family history of breast cancer (19.4% 
vs. 12.8%, p=0.002).  
Mean FCA rates were 38.7% and 37.6% for cases and non-cases, respectively (p=0.05). 
Table 9 gives details of the mean FCA rate by important study characteristics. Mean FCA was 
highest among women under 75 years of age (39.5% vs. 36.3%, p=<0.0001), those consuming 
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 less than 775 mg of calcium per day (38.6% vs. 36.8%, p<0.0001), and those not currently 
taking a vitamin D supplement (38.2% vs. 37%, p<0.0001). Mean FCA did not differ according 
to the season the measure was taken (p=0.16), or current ET use (p=0.51).  
Over a mean 9.6 years of follow-up, 257 women were diagnosed with incident breast 
cancer. Invasive breast cancers accounted for 222 cases while 35 were in situ. Estrogen 
receptor status was obtained for 206 cases and was positive in 175 (85%). Results of the 
Kaplan-Meier survival analysis did not show a significant difference by quartile of FCA, 
plogrank=0.30 (Appendix B). 
In the Cox PH regression analyses, there was a significant positive association between 
FCA and risk of invasive breast cancer in the age adjusted models that persisted in the 
multivariable adjusted models, albeit borderline significant (Table 10). Adjusted for age (as 
timescale), clinic site, weight, menopause age, average total daily calcium intake, ET, and 
family history of breast cancer, FCA was significantly positively related to breast cancer (HR 
1.15 per 1 SD increase in FCA, 95%CI 1.01-1.32, p=0.05). Compared with the lowest quartile of 
FCA, the HR (95%CI) for Q2-Q4 were 1.54 (1.01-2.34), 1.50 (0.99-2.29), and 1.47 (0.96-2.26), 
respectively (ptrend=0.14). A linear contrast for FCA quartile 1 vs. quartiles 2-4 was significant 
(HR 1.50, 95%CI 1.04-2.17, p=0.03). 
An examination of the shape of the risk function using cubic splines did not indicate a 
deviation from a linear relationship (p=0.67) (Appendix B). 
Table 10 Results of the subgroup analyses are presented in . In multivariable models 
comparing dichotomous FCA (quartile 1 vs. quartiles 2-4), there was an increased risk of breast 
cancer associated with higher FCA among women with low (HR 2.34 ≤ 525 mg/d, 95%CI 1.21-
4.52) but not high (HR 1.12 > 525 mg/d, 95%CI 0.71-1.76) dietary calcium intake, although of 
borderline statistical significance (pinteraction=0.06). Investigated individually using likelihood ratio 
tests, there was no interaction between dichotomous FCA and the other subgroup variables 
(i.e., vitamin D supplementation, calcium supplementation, estrogen therapy, total calcium 
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 intake, age) in a multivariable model. In the analysis of FCA by both total calcium intake and 
estrogen therapy, there was no interaction between FCA, calcium and ET in the multivariable 
model of FCA dichotomized at the median (pinteraction=0.23; results not shown). 
Results were similar in multivariable regressions including estrogen receptor positive 
cancer only (HR 1.12 per 1 SD increase in FCA, 95%CI 0.96-1.31) (Table 11). Compared with 
the lowest quartile of FCA, the HR (95%CI) for Q2-Q4 were 1.43 (0.88-2.30), 1.57 (0.99-2.51), 
and 1.39 (0.85-2.25), respectively (ptrend=0.20).  A linear contrast for FCA quartile 1 vs. quartiles 
2-4 was borderline significant (HR 1.46, 95%CI 0.97-2.21, p=0.07).  
5.5 DISCUSSION 
This prospective cohort study of 5035 postmenopausal women from the Study of Osteoporotic 
Fractures showed a modestly significant increased risk of invasive breast cancer with higher 
fractional calcium absorption. A stronger positive association was found among women with low 
dietary calcium intake. However, there was no difference in the magnitude of the association 
between current and not current users of vitamin D supplements, calcium supplements, 
estrogen therapy, by total calcium intake or age. Results were similar for estrogen receptor 
positive tumors.  
Indeed, the hypothesized relationship between calcium and breast cancer prevention is 
not new. Direct effects on cell proliferation and differentiation have been reported in vitro.233, 234 
Furthermore, calcium has been shown to reduce fat-induced cell proliferation in a rodent model 
by maintaining intracellular calcium concentrations.235  The literature is limited regarding calcium 
intake and breast cancer among postmenopausal women and the findings are inconsistent. The 
prospective Cancer Prevention Study II Nutrition Cohort reported a lower risk of breast cancer 
among women with the highest dietary calcium intake, > 1,250 mg/d compared to ≤ 500 mg/d 
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 (p=0.02).123  Two other prospective cohorts, the Women’s Health Study and the Nurses’ Health 
Study, failed to find an association between total calcium intake and postmenopausal breast 
cancer.122, 125 
Likewise, the relationship between vitamin D intake and breast cancer has been 
investigated recently. Vitamin D is hypothesized to reduce breast cancer risk via mechanisms 
similar to, but independent of, calcium. Vitamin D regulates the cell cycle through 
antiproliferative actions and by promoting differentiation.105, 233, 236  Breast tissue can directly 
convert 25(OH)D to 1,25(OH)2D,109 and has also been shown to inhibit mammary 
tumorigenesis.237  Prospective cohort studies of vitamin D intake have not shown an association 
with postmenopausal breast cancer risk.122-125, 238 
It is well documented that intestinal calcium absorption is most efficient when calcium 
intakes are low and decreases with increasing amounts of calcium intake.160  The mechanism 
by which low calcium intake raises fractional calcium absorption is complex. In response to low 
levels of circulating extracellular calcium, the parathyroid gland releases parathyroid hormone 
(PTH). In-turn, PTH up-regulates 25-hydroxy 1-alpha hydroxylase in the kidney, an enzyme 
responsible for converting 25(OH)D to its active form, 1,25(OH)2D.239  In the intestine, 
1,25(OH)2D serves as the hormonal regulator of calcium absorption mediated by the vitamin D 
receptor. The VDR is an intracellular protein, which regulates the expression of vitamin D-
dependent genes, such as calbindin D, a cytosolic protein believed to be the rate-limiting 
molecule in vitamin D-induced intestinal calcium transport.240  Therefore, lower calcium intake, 
resulting in elevated calcium transport, may be the link between higher FCA and increased 
breast cancer risk.  
Recently, the Women’s Health Initiative (WHI) published results of a re-analysis of their 
randomized trial of calcium and vitamin D supplementation on colorectal cancer risk in 
postmenopausal women in which they found a previously unreported interaction with hormone 
therapy. Among women assigned to the placebo HT arms, calcium and vitamin D 
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 supplementation are protective (HR 0.71, 95%CI 0.46-1.09), whereas the opposite was found 
among women assigned to the active HT arms (HR 1.50, 95%CI 0.96-2.33) (pinteraction=0.018).232  
The WHI proposed several mechanisms by which estrogen may interfere with the effect of 
calcium and vitamin D on cancer prevention including increasing intestinal calbindin expression 
independent of vitamin D which would lead to decreased circulating calcium levels and inhibit 
calcium and vitamin D dependent apoptosis, and activating osteoblast formation resulting in 
increased calcium mineralization in bone and reduced bioavailability of systemic calcium.232  
The WHI randomized trial of calcium plus vitamin D on breast cancer risk in postmenopausal 
women did not report any significant effect of supplementation.126  However, these results may 
also be influenced by an unrecognized interaction with hormone therapy and should be re-
analyzed. 
We found a statistically significant difference in mean FCA by age in a bivariate analysis, 
but no difference in the association between FCA and breast cancer risk according to age in a 
multivariable regression. Studies have shown that calcium absorption is lower in 
postmenopausal compared to premenopausal women,162 and that it can be reversed by 
estrogen replacement.162, 163  However, we did not find a difference in mean FCA by ET use in a 
bivariate analysis, a multivariable regression, or in an analysis of FCA by both total calcium 
intake and ET. These findings may have lacked significance due to reduced power for subgroup 
analyses. 
Strengths of this study include its prospective cohort design from the large and long-
standing population-based SOF cohort. We utilized FCA rates measured using a widely 
accepted single isotope method and were able control for a number of factors related to breast 
cancer and FCA. Limitations of this study include our reliance upon a single measure of FCA, 
which may not reflect long-term status. Measurements of potentially mediating factors such as 
level of 25(OH)D, and endogenous estrogen levels were also not available. Most notably, our 
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 study is comprised of elderly, community-dwelling white volunteers and therefore our results 
may not be generalizable to other populations. 
In conclusion, our results suggest that high FCA, particularly among those with a low 
dietary calcium intake, is associated with an increased risk of postmenopausal breast cancer. 
Correlates of FCA, including calcium, vitamin D, and estrogen have been investigated 
individually as etiologic factors for breast cancer. However, with the exception of estrogen, the 
reported associations have been inconsistent. Further investigations into the role of estrogen in 
conjunction with calcium and vitamin D levels on FCA may help to clarify their interdependence. 
Confirmation of the association between FCA and postmenopausal breast cancer is necessary.  
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5.6 TABLES 
Table 8. Descriptive characteristics and risk factors for breast cancer among cases and non-
cases, fourth examination, Study of Osteoporotic Fractures 
 Cases Non-Cases  
 (n=257) (n=4778)  
Characteristic N % N % p-value* 
Clinic Site     0.10 
A 85 33.1 1452 30.4  
B 67 26.1 1017 21.3  
C 39 15.2 924 19.3  
D 66 25.7 1385 29.0  
Age, y, mean(SD) 75.52 (3.85) 76.51 (4.70) <0.0001 
Education     0.29 
< High School 41 16.0 951 19.9  
High School 107 41.6 1924 40.3  
> High School 109 42.4 1899 39.8  
Total Hip BMD, g/cm2, mean(SD) 0.77 (0.12) 0.73 (0.13) <0.0001 
Body Weight, kg, mean(SD) 68.68 (11.78) 66.21 (11.84) 0.001 
Weight Change† -0.50 (4.67) -0.86 (4.97) 0.26 
BMI, kg/m2, mean(SD)‡ 25.83 (4.34) 25.03 (4.27) 0.004 
BMI     0.02 
< 18 1 0.4 81 1.8  
18-24 112 45.0 2421 52.6  
25-29 94 37.8 1505 32.7  
> 30 42 16.9 596 13.0  
Height at age 25 y, cm, mean(SD) 163.12 (5.69) 162.64 (5.82) 0.20 
Age at Menarche, y     0.74 
< 11 27 11.2 569 12.5  
12-13 130 53.7 2464 54.3  
> 14 85 35.1 1508 33.2  
Nulliparous 40 15.6 741 15.5 0.98 
Number of Live Births     0.97 
Never pregnant 40 15.7 741 15.6  
0 8 3.1 117 2.5  
1-2 100 39.2 1914 40.2  
3-4 82 32.2 1533 32.2  
5+ 25 9.8 459 9.6  
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 Table 8. continued 
 Cases Non-Cases  
 (n=257)  (n=4778) 
Characteristic N % N % p-value* 
Age at Menopause, y, mean(SD)  49.06 (4.86) 48.11 (5.71) 0.007 
Age at First Birth, y     0.88 
Never gave birth 31 12.5 555 12.0  
< 20 171 68.7 3261 70.2  
> 20 47 18.9 830 17.9  
Ever Breastfed 64 29.5 1255 31.1 0.62 
Age at Menopause, y     0.15 
< 40 15 7.3 404 10.3  
41-50 113 54.6 2245 57.1  
> 51 79 38.2 1282 32.6  
Surgical Menopause 34 13.8 544 11.8 0.36 
Walks for Exercise 141 54.9 2436 51.1 0.24 
Alcohol, drinks/week, mean(SD) 1.24 (2.50) 1.29 (3.04) 0.76 
Current Alcohol Use  128 49.8 2160 45.3 0.15 
Smoking     0.54 
Never 167 65.0 2931 61.6  
Past 77 30.0 1576 33.1  
Current 13 5.1 252 5.3  
Calcium Intake, mg/d, mean(SD)    
Dietary Calcium  615.08 (363.00) 597.91 (359.98) 0.46 
Supplement Calcium  501.43 (773.80) 392.64 (677.0) 0.03 
Total Calcium 1116.51 (853.18) 990.55 (778.57) 0.02 
Current Calcium Supplement Use 125 48.6 2149 45.0 0.25 
Vitamin D Supplement Use 111 43.2 2010 42.1 0.72 
Current Oral Estrogen Use 66 25.7 887 18.6 0.005 
Benign Breast Disease 40 16.1 678 14.6 0.51 
Family History of Breast Cancer 49 19.4 596 12.8 0.002 
*P-values from t-tests for continuous variables, and chi-square tests for categorical variables 
†Weight change since baseline 
Abbreviations used: BMI, body mass index; SD, standard deviation 
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Table 9. Mean fractional calcium absorption by disease status, personal and behavioral 
characteristics, Study of Osteoporotic Fractures 
 Fractional Calcium Absorption  
Characteristic* Mean SD p-value 
Group    
Cases, n=257  0.387 0.092 0.05† Non-Cases, n=4778 0.376 0.088 
   Age, y 
< 75, n=2128 0.395 0.088 <0.0001† ≥ 75, n=2907 0.363 0.086 
   Total Calcium Intake, mg/d 
≤ 775, n=2512 0.386 0.089 <0.0001† > 775, n=2523 0.368 0.086 
Dietary Calcium Intake, mg/d    
<0.0001† ≤ 525, n=2503 0.382 0.089 
> 525, n=2532 0.371 0.087  
   Season 
Winter, n=1138  0.372 0.088 
Spring, n=1269  0.377 0.087 0.16‡ Summer, n=1068 0.379 0.089 
Fall, n=1560 0.378 0.088 
   Vitamin D Supplement Use 
Current, n=2121 0.370 0.086 <0.0001† Not Current, n=2913 0.382 0.089 
   Oral Estrogen Use 
Current, n=953 0.370 0.083 0.51† Not Current, n=4081 0.377 0.089 
   Height at age 25 y, cm 
0.05† < 163, n=2958 0.379 0.090 
≥ 163, n=2077 0.374 0.090  
   Body Weight, kg 
<0.0001† < 65, n=2549 0.363 0.087 
≥ 65, n=2486 0.391 0.087  
   BMI, kg/m2 
<0.001† <30, n=4395 0.373 0.087 
≥30, n=640 0.403 0.088  
   Alcohol, drinks/week 
0.54† < 1, n=3881 0.377 0.089 
≥ 1, n=1154 0.375 0.085  
   Smoking 
0.97† Current, n=265 0.377 0.093 
Not Current, n=4751 0.377 0.088  
*Comparisons are among the entire analysis population  
†T-test 
‡ANOVA 
Abbreviations used: BMI, body mass index; SD, standard deviation 
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 Table 10. Results of multivariable Cox proportional hazards regressions for association 
between fractional calcium absorption and invasive breast cancer, Study of Osteoporotic 
Fractures 
 Invasive Breast Cancer 
 Age Adjusted Multivariable* Adjusted  
FCA N HR (95%CI) P value N HR (95%CI) P value 
Continuous†  5000 1.14 (1.00-1.30) 0.048 4759 1.15 (1.00-1.32) 0.050 
Categorical‡ 5000   4759   
≤ 0.314  1.00   1.00  
0.315-0.372  1.53 (1.01-2.30) 0.043  1.54 (1.01-2.34) 0.046 
0.373-0.434  1.51 (1.01-2.28) 0.046  1.50 (0.99-2.29) 0.057 
≥ 0.435  1.46 (0.97-2.20) 0.073  1.47 (0.96-2.26) 0.079 
ptrend   0.124   0.138 
Dichotomous§ Cases /   Cases /  
 Non-cases  Non-cases  
Age      0.86** 
<75 years 112/1997 1.01 (0.61-1.65) 0.97 107/1904 1.15 (0.68-1.95) 0.60 
≥75 years 110/2781 2.09 (1.26-3.47) 0.004 107/2641 1.86 (1.12-3.11) 0.02 
Dietary Calcium Intake      0.06** 
≤ 525 mg/d 108/2380 2.30 (1.23-4.30) 0.009 103/2269 2.34 (1.21-4.52) 0.01 
> 525 mg/d 114/2398 1.15 (0.74-1.79) 0.53 111/2276 1.12 (0.71-1.76) 0.64 
Calcium Supplement      0.44** 
Not Current  121/2628 1.33 (0.80-2.20) 0.27 117/2500 1.31 (0.78-2.21) 0.30 
Current 101/2149 1.67 (1.01-2.76) 0.04 97/2045 1.63 (0.97-2.75) 0.06 
Total Calcium Intake      0.66** 
≤ 775 mg/d 102/2402 1.63 (1.91-2.92) 0.10 100/2284 1.70 (0.92-3.12) 0.09 
> 775 mg/d 120/2376 1.46 (0.93-2.30) 0.10 114/2261 1.38 (1.86-2.19) 0.18 
Vitamin D Supplement      0.56** 
Not Current  127/2767 1.43 (0.88-2.31) 0.15 123/2629 1.37 (0.83-2.26) 0.21 
Current 95/2010 1.57 (0.93-2.66) 0.09 91/1916 1.61 (0.93-2.79) 0.09 
Oral Estrogen Use      0.23** 
Not Current 166/3890 1.52 (1.01-2.31) 0.05 159/3701 1.50 (0.98-2.30) 0.06 
Current 56/887 1.42 (0.71-2.82) 0.32 55/844 1.54 (0.74-3.17) 0.24 
*Adjusted for age (as timescale), clinic site, weight, menopause age, calcium intake, vitamin D 
supplementation, estrogen therapy, and family history of breast cancer 
†Hazards ratios in this row are for a 1 SD (8.8%) increase in fractional calcium absorption 
‡Quartile distribution among entire cohort; range 0.11-0.74 
§Hazard ratios comparing FCA dichotomized at quartile 1 (0.314) 
**P-value for interaction between subgroup variable and FCA 
Abbreviations used: CI, confidence interval; FCA, fractional calcium absorption; HR, hazard ratio; SD, 
standard deviation  
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 Table 11. Results of multivariable Cox proportional hazards regressions for association between 
fractional calcium absorption and estrogen receptor positive breast cancer, Study of Osteoporotic 
Fractures 
 Estrogen Receptor Positive 
 Age Adjusted Multivariable* Adjusted 
FCA N HR (95%CI) P value N HR (95%CI) P value 
       
Continuous†  4953 1.12 (0.97-1.30) 0.14 4713 1.12 (0.96-1.31) 0.15 
       
Categorical‡ 4953   4713   
≤ 0.314  1.00   1.00  
0.315-0.372  1.38 (0.87-2.20) 0.17  1.43 (0.88-2.30) 0.15 
0.373-0.434  1.56 (0.99-2.44) 0.05  1.57 (0.99-2.51) 0.06 
≥ 0.435  1.37 (0.87-2.17) 0.18  1.39 (0.85-2.25) 0.19 
ptrend   0.18   0.20 
       
*Adjusted for age (as timescale), clinic site, weight, menopause age, average total daily calcium intake, 
oral estrogen use, and family history of breast cancer 
†Hazards ratios in this row are for a 1 SD (8.8%) increase in fractional calcium absorption 
‡ Quartile distribution among entire cohort; range 0.11-0.74 
Abbreviations used: CI, confidence interval; FCA, fractional calcium absorption; HR, hazard ratio; SD, 
standard deviation  
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 6.1 ABSTRACT 
Breast cancer occurrence is positively related to bone mineral density (BMD), but previous 
studies have been limited to short follow-up durations and have not accounted for recurrent 
BMD measures. In this prospective study, we examined the association of an initial BMD 
measure and change in BMD on breast cancer risk in the Study of Osteoporotic Fractures 
(SOF), a cohort of 9,704 Caucasian, postmenopausal women. Total hip BMD was measured 
twice, a mean 3.5 years apart in 5383 women, 263 of whom later developed an incident case of 
breast cancer. A Cox proportional hazards analysis was performed to compute hazard ratios 
(HRs) and 95% confidence intervals (95%CIs). Mean time between the repeat BMD measure 
and breast cancer diagnosis was 9.5 years. Mean BMD was significantly higher among cases 
compared to non-cases for both the initial and repeat measures (p<0.0001). In multivariable 
models, there was no association between increasing levels of BMD and invasive breast cancer 
(HR 1.06 per 1 SD increase, 95%CI 0.88-1.20). Compared with the lowest category of BMD T-
score (≤ -2.5), women with higher T-Scores (-2.5 to -1.0, and ≥ -1.0) had relative risks (HR, 
95%CI) of 1.99 (1.03-3.85), and 2.01 (1.00-4.01), respectively (p=0.07). Change in BMD 
(annualized % change between initial and repeat measure) was not associated with a significant 
increased risk of breast cancer (HR 1.09 per 1 SD increase, 95%CI 0.93-1.26). Similar results 
were obtained in a combined model with initial BMD and change in BMD. In a subgroup analysis 
of initial BMD dichotomized at the median, the effect of BMD was dependent upon family history 
(pinteraction=0.01). Women with a positive family history and high BMD had a 3 times higher risk of 
breast cancer (95%CI 1.25-7.12) compared to women with low BMD. In this prospective study 
of postmenopausal women, the effect of higher BMD on breast cancer risk varied by family 
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 history of breast cancer. These results support an increased risk of breast cancer over a long 
follow-up period among women with low to normal T-scores compared to osteoporotic women. 
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 6.2 INTRODUCTION 
Estrogen is thought to play a central role in the development of breast cancer due to its ability to 
stimulate proliferation of breast tissue.175  Factors that increase exposure of breast tissue to 
estrogens, such as early menarche, older age at first birth, or late menopause, are associated 
with breast cancer risk.176  Indeed, prolonged exposure to high levels of endogenous estrogens 
may increase breast cancer risk in postmenopausal women.177  However, it is difficult to classify 
a woman’s long-term exposure to endogenous estrogen by a single measurement because 
serum estrogen levels are highly variable over time.178 
Bone mineral density, on the other-hand, is thought to be a surrogate measure of lifetime 
estrogen exposure.179  Bone contains estrogen receptors and is sensitive to circulating estrogen 
levels.180  BMD is positively correlated with endogenous estrogen levels,181 early menarche, 
parity, and the length of a woman’s reproductive lifecycle.182  In addition to the underlying age 
related decrease, BMD also decreases in postmenopausal women, mostly due to estrogen 
deprivation beginning at the time of menopause. Even among postmenopausal women, 
however, the rate of bone loss is variable. Factors affecting postmenopausal bone loss include 
sustained estrogen exposure due to exogenous estrogen use and/or endogenous estrogen 
released from fat, calcium and vitamin D intake from dietary and supplemental sources, and 
level of physical activity. 
Higher BMD, reflecting higher estrogen exposure throughout life, has been shown to 
predict future breast cancer in older women.184  Data supporting the BMD-breast cancer link 
were initially published by SOF investigators more than a decade ago. To update the early SOF 
reports which had fewer than 4 years of follow-up,184, 195 we investigated the relationship 
between BMD and breast cancer among postmenopausal women after 13 years of follow-up 
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 (mean 9.5 years). Specifically we studied the long-term association of BMD and risk of invasive 
and estrogen receptor (ER+) positive breast cancer. Furthermore, we tested the hypothesis that 
the risk associated with an initial BMD measure would be strengthened by the addition of a 
repeat BMD measure (annual percent change) assessed 3.5 years later. We also tested 
whether this association differed by body mass index (BMI), hormone therapy, and family 
history of breast cancer as secondary aims. 
6.3 METHODS 
6.3.1 Study Population 
The Study of Osteoporotic Fractures (SOF) is a longitudinal cohort of 9,704 Caucasian, 
community-dwelling postmenopausal women aged 65 and older who were recruited at 4 US 
clinical centers between 1986 and 1988.  At the baseline (V1) examination, women provided 
informed consent and risk factor and health measures were collected through physical 
measurements, questionnaires, and functional assessments. Women with a history of bilateral 
hip replacements and those who were unable to walk unassisted were excluded.210 
Total hip bone mineral density was measured at the second (V2) and fourth (V4) clinic 
visits, approximately 2 and 6 years after enrollment. All SOF participants with matching V2 and 
V4 hip BMD measures were eligible for the current analysis. Individuals reporting a history of 
breast cancer at enrollment (n=269) and those with missing outcome data (n=336) were 
excluded. In order to compare the same breast cancer outcomes, only incident cases diagnosed 
after the V4 repeat measure are included. The 136 incident cases diagnosed prior to V4 were 
excluded. Follow-up for incident breast cancer cases begins after the V4 repeated hip BMD 
measure and continued through December 2006 at which time the women were censored who 
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 did not develop breast cancer, experience death, or were not lost to follow-up. The analysis 
population was therefore comprised of 263 cases and 5120 non-cases. The study timeline is 
detailed in Figure 6 and the selection process in Figure 7. 
 
  
 
        
Figure 6. Timeline of total hip bone mineral density measurements and follow-up period, Study of 
Osteoporotic Fractures  
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263 Cases 
5120 Non-Cases 
Hip BMD Measure 
8074 
Between Baseline and V4 
142 Terminated 
933 Died 
213 Postcard only 
4 Lost to follow-up 
488 Home visit 
1309 Questionnaire only 
285 Minimal data 
Total in SOF Cohort 
9,704 
(1986-1988) 
V2 Clinical Exam 
8,098 
Total in Analysis 
5383 
2417 V2 or V4 BMD measure only  
93 Miss-matched hip measure 
269 History of breast cancer at enrollment 
136 Incident breast cancer diagnosed before V4 
336 Missing* outcome 
Eligible for Clinic V4 
8,412 
(1992-1994) 
Between Baseline and V2 
39 Terminated 
253 Died 
72 Postcard only 
1 Lost to follow-up 
Eligible for Clinic V2 
9,339 
(1989-1990) 
V4 Clinical Exam 
6,330 
1021 Questionnaire only 
  220 Minimal data 
Hip BMD Measure 
6211
 
Figure 7. Cascade of analysis population determination, Study of Osteoporotic Fractures 
 *Missing values coded as refused to answer (n=63), unable to answer (n=8), never had a period 
(n=265). 
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 6.3.2 Bone Mineral Density Measurements 
Details of the BMD measures have been published previously.210, 213  Briefly, total hip BMD 
(bone mineral density, g/cm2, of the proximal femur) was measured at V2 and V4 using dual-
energy x-ray absorptiometry (DXA) (QDR 1000, Hologic Inc., Bedford, Massachusetts). The 
mean coefficient of variation was 1.2% for the femoral neck. BMD was categorized into quintiles 
based in on the distribution in the SOF cohort with cutpoints at 0.648, 0.721, 0.782, and 0.86. T-
scores were calculated using the National Health and Nutrition Examination Survey reference 
values,241 and categorized based on the World Health Organization Criteria for the Diagnosis of 
Osteoporosis in Caucasian Women; normal bone mass is less than or equal to 1 SD below the 
young-adult mean, low bone mass is between 1 and 2.5 SD below the young-adult mean, 
osteoporosis is greater than or equal to 2.5 SD below the young-adult mean.242  The rate of 
change in BMD was calculated using the total hip BMD measures taken at V2 and V4, and 
expressed as the annualized percent change over a mean 3.5 years. 
6.3.3 Covariate Information 
At the baseline and V2 examinations, participants completed a questionnaire and were 
interviewed. Demographic (age, education), reproductive history (menarche age, parity, age at 
first birth, number of live births, breastfeeding), height at age 25, menopausal status 
(menopause age, surgical vs. natural menopause), and breast cancer risk factor (benign breast 
disease, family history of breast cancer) data were collected at the baseline examination. At the 
V2 examination, updated data concerning smoking status, alcohol use, and physical activity 
were collected. Body weight was measured using a balance-beam scale. BMI was calculated by 
dividing the V2 weight by the square of height at age 25 years. Estrogen therapy (ET) was 
defined as currently taking estrogen pills. Current supplemental vitamin D use was defined as 
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 taking vitamin D or a multivitamin containing vitamin D at least once per week. Calcium 
supplementation was determined by asking about current use at least once per week. Variables 
were categorized based on common cutpoints (e.g. BMI) or the original response categories 
collapsed to prevent small cell counts (e.g. age at first birth).  
6.3.4 Incident Breast Cancer Ascertainment 
Follow-up occurred every four months by either postcard or telephone (98% complete) in 
addition to clinic visits approximately every 2 years. Breast cancer outcomes were ascertained 
through self-report or death certificate review and were adjudicated by physicians locally and 
centrally at the San Francisco Coordinating Center. Medical records and pathology reports were 
used to record information on date of breast cancer diagnosis, stage at diagnosis, and estrogen- 
and progesterone-receptor status.184 
6.3.5 Statistical Analyses 
As part of the preliminary data analysis, baseline characteristics of the analysis population and 
the remainder of the SOF cohort were compared using t-tests for continuous measures and chi-
square tests for categorical data. Additionally, change in important characteristics between V2 
and V4 were assessed for the analysis population. Mean T-score per quintile of initial BMD also 
was calculated. Finally, the distribution of baseline characteristics (measured at V1 or V2) of the 
analysis population were compared for cases and non-cases.  
 The main analysis used Cox proportional hazard regression models with age as the 
underlying time scale to estimate hazard ratios and 95% confidence intervals for the association 
between bone mineral density and the risk of breast cancer.217-219  Entry time was defined as 
age at V4 in days (calculated by multiplying V4 age by 365.25). Exit time was defined as age at 
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 breast cancer diagnosis, death, loss to follow-up, or censoring (calculated by adding follow-up 
time in days from V4 to entry age). BMD was assessed 3 ways: 1) initial V2 BMD alone, 2) 
change in BMD between the initial and repeated measure, and 3) a combined model of initial 
BMD plus the change in BMD. Continuous BMD measures were expressed per one standard 
deviation (SD) increase in BMD. Initial BMD levels also were assessed as quintiles based on 
the distribution of BMD in the entire SOF cohort; the lowest category served as the reference. 
BMD was further assessed by T-score category with the osteoporotic group as the reference. 
Potential confounders, described above, were evaluated for inclusion in the multivariable 
adjusted models based on their significance (p<0.25) in the bivariate analyses. Correlated 
variables, e.g. multiple measures of body size, were chosen as covariates based upon statistical 
association, scientific knowledge, and/or variable distribution. Dummy variables were created for 
categorical variables as appropriate. Variables were selected for elimination one at a time using 
a backward elimination strategy based on individual Wald tests.222, 223  After each variable was 
removed from the model, the partial likelihood ratio test was calculated comparing the nested 
models. Removed variables remained out of the models if no significant contribution to the 
model was determined (p≥0.1). Interactions were evaluated using likelihood ratio tests that 
compared the model with the interaction term to the main effects model (p≤0.05). 
 The potential for non-linear effects was investigated using cubic splines. RCS (restricted 
cubic splines), a SAS macro, was used to fit the cubic splines.221  Knot placement was set at the 
BMD quintile cut-points. All breast cancers including in situ and invasive only breast cancers 
were analyzed separately. While the inclusion of in situ did not affect the results, regression 
results for invasive only cancers are presented. Analyses are also repeated among subgroups 
defined by age (split at median < 75 vs. ≥ 75 years), BMI (< 30 and ≥ 30 kg/m2), ET (current/not 
current), and family history of breast cancer (negative/positive). Likelihood ratio tests were used 
to evaluate possible interactions between the subgroup variable and BMD by comparing a 
multivariable model with and without the interaction term expressed as the product of the 
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 variable and dichotomous BMD.  For the final models, probability values <0.05 were considered 
statistically significant. All tests were two-tailed. Schoenfeld residuals were used to test the 
proportional hazards assumption. SAS software release 9.2 (SAS Institute Inc., Cary, NC) was 
used for all analyses. 
6.4 RESULTS 
This prospective cohort study investigated the relationship between bone mineral density and 
breast cancer among 5383 postmenopausal women enrolled in the study of osteoporotic 
fractures. Baseline characteristics of the analysis population and the remainder of the SOF 
cohort (i.e. non-participants) are provided in Table 12. Meaningful differences were that the 
analysis population tended to be younger at enrollment and experience menopause later, were 
less likely to be current smokers or have a positive family history of breast cancer, and were 
more likely to be current users of calcium supplements, vitamin D supplements, and estrogen 
therapy and to walk for exercise.  
The mean age of women at V2 was 72.7 years. The mean total hip BMD was 0.76 g/cm2 
(T-score of -1.34). Changes in important participant characteristics between V2 and V4 for the 
analysis population are provided in Table 13. At V4 a smaller proportion of women were current 
smokers, and a greater proportion of women were current users of calcium supplements, 
vitamin D supplements, and estrogen therapy. Mean T-scores by quintile of BMD at V2 are 
displayed in Table 14.  
After a mean 9.52 years of follow-up after V4, 263 incident breast cancer cases were 
identified. Invasive breast cancers accounted for 224 cases while 39 were in situ. Estrogen 
receptor status was obtained for 206 cases and was positive in 178 (86%). 
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 Table 15 presents the characteristics of the analysis population at baseline or V2. 
Women with breast cancer were slightly younger and more likely to be heavier, taller, and walk 
for exercise. As expected, breast cancer risk factors including older age at menopause, 
estrogen therapy use, and family history of breast cancer were found to be more prevalent in 
the incident cases than the non-case group. 
Results of the Cox proportional hazards regression analyses are presented in Table 16. 
In Model 1, the initial BMD measure was a significant predictor of incident breast cancer risk in 
the age adjusted models. The positive association persisted in multivariable models, but was 
attenuated with the addition of weight as a covariate. Adjusted for age (as time scale), clinic site, 
weight, vitamin D supplement use, ET, and family history of breast cancer, initial BMD was not 
associated with and increased risk of invasive breast cancer (HR 1.06 per 1 SD increase in 
BMD, 95%CI 0.88-1.20). By quintile, with the lowest BMD level serving as the reference, the HR 
(95%CI) for increasing categories were 1.09 (0.64-1.85), 1.39 (0.84-2.31), 1.44 (0.87-2.39), and 
1.13 (0.66-1.95), respectively (p=0.43). Compared to the lowest T-score category (≤ 2.5 
corresponding to the WHO designation of osteoporosis), the HR (95%CI) for increasing 
categories were 1.99 (1.03-3.85) and 2.01 (1.00-4.01), respectively (p=0.07).  In Model 2, 
change in BMD was not a significant predictor of incident breast cancer risk in the age adjusted, 
or either of the multivariable adjusted models (HR 1.09 per 1 SD increase, 95%CI 0.93-1.27). In 
Model 3, the risk estimates were similar to those in the earlier models with initial BMD or change 
in BMD alone.  
Results were similar in multivariable regressions including estrogen receptor positive 
cancer only (Table 17). In Model 1, initial BMD was not associated with and increased risk of 
ER+ breast cancer (HR 1.04 per 1 SD increase, 95%CI 0.878-1.24). Compared to the lowest T-
score category, the HR (95%CI) for increasing categories were 2.75 (1.19-6.33) and 2.45 (1.02-
5.86), respectively (p=0.02). In Model 2, change in BMD was not a significant predictor (HR 1.06 
 100 
 per 1 SD increase, 95%CI 0.90-1.26). In Model 3, containing both initial BMD and BMD change, 
the risk estimates were similar.  
Results of the subgroup analyses are presented in Table 18. In multivariable models 
with initial BMD dichotomized at the median, higher BMD was associated with an increased risk 
of invasive breast cancer among women with a positive (HR 2.99, 95%CI 1.25-7.12) but not a 
negative (HR 1.07, 95%CI 0.77-1.50) family history of breast cancer (pinteraction=0.01). There was 
no difference in the magnitude of the association by age, ET, or BMI. Investigated individually 
using likelihood ratio tests, no other interactions between dichotomous BMD and the subgroup 
variable in a multivariable model were found. 
An examination of the shape of the risk function using cubic splines did not indicate a 
deviation from a linear relationship for BMD overall (p=0.11), or by family history of breast 
cancer (negative family history p=0.20, positive family history p=0.17) (Appendix C). 
6.5 DISCUSSION 
In this large, prospective, cohort study of 5383 postmenopausal women from the Study of 
Osteoporotic Fractures, we examined the association between BMD and the development of 
breast cancer over an average of 9.5 years. Overall a continuous BMD measure was not 
associated with breast cancer risk after adjusting for known breast cancer risk factors including 
weight, ET, and family history. Furthermore, there was no improvement in the overall predictive 
value with a second measure of BMD, obtained over a mean 3.5 years later, in the 
determination of breast cancer risk. Results were similar for estrogen receptor positive breast 
cancer. We found a significantly increased risk of invasive breast cancer with total hip T-score 
measures in the normal (≥ -1.0) and low (-1.0 to -2.5) ranges compared to osteoporotic (≥ -2.5) 
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 based on WHO criteria. Having a positive family history of breast cancer was associated with a 
significant 3-fold increase in breast cancer risk among women with high compared to low BMD. 
Data supporting the BMD-breast cancer link were initially published by SOF investigators 
between 1996 and 2001 with follow-up ranging from 3 to 6 years.184, 195, 196, 200  Several other 
prospective studies have sought to confirm this association, and found a similar or slightly 
weaker relationship,190-194 while other still found no association.204, 205  Furthermore, a recent 
analysis from the Women’s Health Study found that BMD predicted breast cancer risk 
independent of Gail score.208  The fact that we did not find an overall association between BMD 
and breast cancer risk, indicates that BMD may be a stronger predictor of early opposed to later 
breast cancer risk as we did not include incident cancers that occurred within approximately 4 
years following the initial hip BMD scan. Nevertheless, we are using BMD as a measure of long-
term exposure. 
While the relationship between higher BMD and an increased risk of breast cancer in 
postmenopausal women has been well studied, the association is moderate at best. One reason 
that a stronger association has not been documented, may be that among women with higher 
BMD, their estrogen exposure has diminished resulting in an attenuated increased risk of breast 
cancer. Or conversely, among women with low BMD, their exposure to estrogen has been 
sustained essentially negating the protective effect of having a lower BMD.  
To our knowledge, this is the first study to investigate the predictive value of a repeat 
BMD measurement compared with the initial BMD among postmenopausal women. We found 
change in BMD not to be a risk factor for breast cancer. The one study to have looked at 
change in BMD over 6.9 years and the risk of breast cancer did so only among peri-menopausal 
women aged 45-54.204  With only 34 incident breast cancer cases, they too found no 
relationship with a mean follow-up of 9.7 years. The HR (95%CI) for 1 SD change in BMD at the 
femoral neck was 1.15 (0.79-1.68). Our results also suggest that a repeat BMD measure does 
not add value in determining future breast cancer risk. 
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 The risk of breast cancer related to BMD has been reported to differ by estrogen 
receptor status197 and family history of breast cancer. Results regarding family history come 
from a separate cohort study190 and from an early SOF report which utilized cases that were 
diagnosed within the first 3.5 years of follow-up and that do not overlap with the cases in this 
analysis.195  While our results were similar for invasive and estrogen receptor positive breast 
cancers, we did find a significant dependence on family history in the relationship between BMD 
and breast cancer. Indeed, these women may be more sensitive to cumulative estrogen 
exposure as reflected by their BMD measurements. Genetic differences in estrogen synthesis, 
metabolism, and the enzymes involved could account for the association due to altered 
bioavailability and/or biologic activity of steroid hormones such as estrogen.243   
Our study has several important strengths in that it is a large prospective study of 
postmenopausal women, with repeated and rigorously controlled BMD measurements. The 3.5 
year interval present in this analysis reflects the time between repeat BMD measurements 
common in clinical practice. Additionally, incident breast cancer diagnoses were confirmed by 
pathology records and adjudicated by a physician and detailed covariate information was 
collected. 
Limitations of our study include the fact that women who were able to attend the follow-
up examination to have their BMD measurement were healthier than those who did not attend 
the follow-up examination. Those who did not attend, were likely to have been older, weaker, 
and possibly may have had greater BMD loss. Thus, our results are relevant to healthy 
postmenopausal white women aged 65 and greater, and may not be generalizable to other 
populations. Furthermore, we lacked data regarding disease history in more distant relatives, 
aunts and grandmothers for instance, as well as paternal family history.    
In conclusion, BMD was not found to be a significant long-term predictor of breast 
cancer risk after multivariable adjustment. Furthermore, a repeat BMD measure does not 
appreciably enhance the predictive value. However, our results do indicate that the association 
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 between bone mineral density and invasive breast cancer is modified by family history of breast 
cancer. Women with a positive family history coupled with high BMD are at increased risk. 
Identifying women at elevated risk is a critical step towards breast cancer risk reduction. 
Because preventive interventions are limited, continued vigilance in breast cancer screening is 
recommended for these women into old age. Routine screening can result in earlier detection of 
breast carcinomas, less invasive treatment options, better outcomes, and increased survival.  
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 6.6 TABLES 
Table 12. Baseline characteristics of the analysis population and non-participants, Study of 
Osteoporotic Fractures 
Analysis 
Population 
Non- 
  Participants 
(n=5383) (n=4321) 
Characteristic Mean SD Mean SD p-value 
Age, y 70.69 4.64 72.80 5.66 <0.0001 
Education, y 12.81 2.73 12.30 2.79 <0.001 
Body Weight, kg 67.15 11.83 66.82 12.26 0.19 
BMI, kg/m2 26.39 4.38 26.42 4.59 0.72 
Height at Age 25 y, cm 162.60 15.82 162.50 5.65 0.75 
Age at Menopause, y 48.11 45.75 47.71 5.79 <0.01 
Age at Menarche, y 13.02 1.44 13.06 1.50 0.23 
Number of Live Births 2.72 1.53 2.54 1.48 <0.001 
Alcohol Use, drinks/week 1.90 3.90 1.93 4.3 0.72 
  N % N % 
Clinic Site      
A 1524 28.31 934 21.62 
B 1211 22.50 1210 28.00 
C 1171 21.75 1253 29.00 0.42 
D 1477 27.44 924 21.38 
Nulliparous 843 15.67 731 16.93 0.10 
Age at First Birth, y      
< 20 633 14.63 562 19.00 
21-30 3040 70.24 1973 66.70 
31-40 633 14.63 408 13.79 <0.001 
> 40 22 0.51 15 0.51 
Ever Breastfed 3108 68.52 2468 68.88 0.73 
Surgical Menopause 645 12.44 512 12.40 0.95 
Walks for Exercise 2951 54.83 1915 44.33 <0.0001 
Current Smoker  450 8.38 517 12.01 <0.0001 
Current Calcium Supplement Use 2356 43.85 1776 41.20 <0.01 
Current Vitamin D Supplement Use 2441 46.14 1832 43.25 <0.01 
Current Oral Estrogen Use 818 15.37 513 12.08 <0.0001 
Family History of Breast Cancer 689 13.17 605 15.14 <0.01 
Abbreviations used: BMD, bone mineral density; BMI, body mass index; SD, standard deviation 
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 Table 13. Change in important participant characteristics between the second and fourth clinic 
visits, analysis population (N=5383), Study of Osteoporotic Fractures 
 V2 V4  
Characteristic Mean SD Mean SD p-value* 
Age, y 72.71 4.62 76.45 4.63 <0.01 
Body Weight, kg 66.60 11.77 66.26 11.97 0.14 
BMI, kg/m2, mean(SD) 26.21 4.37 26.44 4.52 0.01 
Total Hip BMD, g/cm2 0.76 0.13 0.74 0.13 <0.01 
  N % N % 
Current Smoker  372 6.95 296 5.50 <0.001 
Current Calcium Supplement Use 2034 38.65 2401 44.61 <0.001 
Current Vitamin D Supplement Use 2137 40.53 2247 41.75 <0.001 
Current Oral Estrogen Use 8584 16.24 1046 19.44 <0.001 
*P-values from paired t-tests for continuous variables, and two-dependent proportion chi-square tests for 
categorical variables 
Abbreviations used: BMD, bone mineral density; BMI, body mass index; SD, standard deviation 
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 Table 14. Mean T-score by quintile of BMD at V2, analysis population, Study of Osteoporotic 
Fractures 
 T-score 
BMD Quintile, g/cm2 N Mean SD 
≤ 0.648 975 -2.72 0.41 
0.649-0.721 1065 -1.95 0.16 
0.722-0.782 1094 -1.44 0.13 
0.783-0.860 1110 -0.91 0.17 
≥ 0.861 1139 0.08 0.62 
Abbreviations used: BMD, bone mineral density; SD, standard deviation 
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 Table 15. Descriptive characteristics and risk factors for breast cancer among cases and non-
cases, analysis population, Study of Osteoporotic Fractures  
 Cases Non-cases  
(N=263) (N=5120) 
Characteristic N % N % p-value* 
     Clinic Site 
A 82 31.18 1442 28.16 
B 66 25.10 1145 22.36 
C 48 18.25 1123 21.93 0.31 
D 67 25.48 1410 27.54 
71.79 3.77 72.75 4.66 <0.0001 Age, y, mean(SD) 
     Education 
< High School 39 14.83 1001 19.57 
0.16 High School 113 42.97 2067 40.42 
> High School 111 42.21 2049 40.01 
Body Weight, kg, mean(SD) 68.98 11.63 66.48 11.76 0.001 
26.83 4.54 26.18 4.36 0.02 BMI, kg/m2, mean(SD) 
163.26 5.62 162.54 5.83 0.05 Height at age 25 y, cm, mean(SD) 
     Age at Menarche, y 
< 11 24 9.72 602 12.29 
12-13 138 55.87 2691 54.95 0.47 
> 14 85 34.41 1604 32.75 
42 15.97 801 15.65 0.89 Nulliparous 
     Age at First Birth, y 
Never gave birth 30 11.76 603 12.06 
0.98 < 20 178 69.80 3495 69.89 
> 20 47 18.43 903 18.06 
     Number of Live Births, mean(SD) 
Never pregnant 42 16.09 801 15.69 
0 6 2.30 130 2.55 
1-2 99 37.93 2079 40.73 
3-4 91 34.87 1603 31.41 
0.79 
5+ 23 8.81 491 9.62 
Ever Breastfed 64 28.96 1364 31.61 0.41 
48.88 4.93 48.07 5.78 0.02 Age at Menopause, y, mean(SD)  
38 14.90 607 12.31 0.22 Surgical Menopause 
158 60.08 2793 54.56 0.08 Walks for Exercise 
1.89 3.65 1.90 3.91 0.97 Alcohol, drinks/week, mean(SD) 
15 5.75 357 7.01 0.43 Current Smoker 
103 40.55 1931 38.56 0.52 Current Calcium Supplement Use 
93 36.47 2044 40.74 0.17 Current Vitamin D Supplement Use 
56 21.88 802 15.96 Current Oral Estrogen Use 0.01 
Benign Breast Disease 45 17.72 743 14.90 0.23 
Family History of Breast Cancer† 49 18.92 640 12.87 0.005 
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 Table 15. continued 
 Cases Non-cases  
(N=263) (N=5120) 
Characteristic N % N % p-value* 
Initial BMD at V2      
Total Hip, g/cm2, mean(SD) 0.79 0.12 0.76 0.13 <0.0001 
 T-score        
≤ -2.5 13 4.94 622 12.15 
<0.0001 > -2.5 to -1.0 135 51.33 2755 53.81 
≥ -1.0  115 43.73 1743 34.04 
Repeat BMD at V4      
Total Hip, g/cm2, mean(SD) 0.77 0.12 0.73 0.13 <0.0001 
T-score      
≤ -2.5 21 7.98 904 17.66 
<0.0001 > -2.5 to -1.0 146 55.51 2835 55.37 
≥ -1.0  96 36.50 1381 26.97 
Annual % BMD change, mean(SD)‡  -0.43 1.29 -0.58 1.43 0.07 
*P-values from t-tests for continuous variables, and chi-square tests for categorical variables 
†Self-reported breast cancer diagnosis in a first degree female relative (i.e. mother or sister) 
‡Over a mean (SD) 3.54 (0.30) years between measurements 
Abbreviations used: BMD, bone mineral density; BMI, body mass index; SD, standard deviation 
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 Table 16. Results of multivariable Cox proportional hazards regression to predict risk of 
invasive breast cancer with initial and change in total hip BMD measures, Study of 
Osteoporotic Fractures 
 Invasive Breast Cancer 
 Age  Multivariable 
Adjusted‡  
Multivariable 
Adjusted‡  Adjusted 
Cases / Non-Cases 224 / 5119 214 / 4872 210 / 4769 
HR HR HR P valueP value P value Model (95%CI) (95%CI) (95%CI) 
       
 1: Initial BMD      
1.19 1.14 1.06 Continuous* 0.01 0.06 0.75 (1.04-1.35) (0.99-1.30) (0.88-1.20) 
Quintiles       
≤ 0.648 1.00 1.00 1.00 
0.649-0.721 1.18 1.19 1.09  
(0.70-1.97) (0.70-2.01) (0.64-1.85) 
0.722-0.782 1.62 1.56 1.39 0.01§ 0.04§ 0.49§ 
(1.00-2.63) (0.95-2.57) (0.84-2.31) 
0.783-0.860 1.75 
 0.06**  0.15**  0.43** 
1.72 1.44 
(1.09-2.81) (1.06-2.80) (0.87-2.39) 
≥ 0.861 1.68 1.52 1.13 
(1.04-2.70) (0.93-2.49) (0.66-1.95) 
T-score       
1.00 ≤ -2.5 1.00 1.00 
2.09 2.21 1.99 <0.01§ 0.01§ 0.19§ > -2.5 to -1.0 (1.12-3.88) (1.15-4.24) (1.03-3.85) <0.01** <0.01**  0.07** 
2.56 2.54 2.01 ≥ -1.0 (1.36-4.81) (1.31-4.93) (1.00-4.01) 
       
2: Change in BMD† 1.09 1.10 1.09 0.28 0.19 0.70  (0.93-1.26) (0.95-1.28) (0.94-1.25) 
       
3: Initial BMD 1.18 1.13 1.03 0.01 0.07 0.75 (1.04-1.35) (0.99-1.30) (0.88-1.20) 
    Change in BMD 1.08 1.10 1.09 0.33 0.23 0.28 (0.93-1.25) (0.94-1.28) (0.93-1.27) 
       
*Per 1 SD (0.13 g/cm2) increase in BMD 
†Per 1 SD (1.42%) increase in BMD 
‡Adjusted for age (as time scale), clinic site, vitamin D supplement use, estrogen therapy use, and family 
history of breast cancer; the final multivariable model additionally includes an adjustment for weight 
§P value for trend 
**Overall p value 
Abbreviations used: BMD, bone mineral density; CI, confidence interval; HR, hazard ratio; SD, standard 
deviation 
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 Table 17. Results of multivariable Cox proportional hazards regression to predict risk of ER+ 
breast cancer with initial and change in total hip BMD measures, Study of Osteoporotic Fractures 
 Estrogen Receptor Positive 
 Age  Multivariable 
Adjusted‡ 
Multivariable 
Adjusted‡ Adjusted 
Cases / Non-Cases 178 / 5119 172 / 4872 168 / 4769 
HR HR HR Model P value P value P value (95%CI) (95%CI) (95%CI) 
       
 1: Initial BMD      
1.22  1.16 1.04  Continuous* 0.008 0.07 0.66 (1.05-1.40) (1.00-1.34) (0.87-1.24) 
Quintiles       
≤ 0.648 1.00 1.00 1.00 
0.649-0.721 1.09 1.06 0.97 
(0.60-1.98) (0.58-1.93) (0.53-1.78) 
0.722-0.782 1.93   0.02§   0.59§ 1.84 1.63   0.06§ 
(1.13-3.31) (1.07-3.17) (0.94-2.84) 
0.783-0.860 1.70 
  0.04**   0.16** 0.07**   1.65 1.36 
(0.98-2.93) (0.96-2.86) (0.77-2.41) 
≥ 0.861 1.72 1.09 1.52 
(1.00-2.96) (0.59-2.01) (0.87-2.63) 
T-score       
1.00 ≤-2.5 1.00 1.00 
3.15 3.08 2.75    0.01§    0.03§ 0.37§ >-2.5 to -1.0 (1.38-7.21) (1.34-7.05) (1.19-6.33) <0.01** <0.01** 0.02** 
3.50  3.21 2.45  ≥-1.0 (1.52-8.08) (1.38-7.44) (1.02-5.86) 
       
2: Change in BMD† 1.07  1.08 1.06  0.42 0.36 0.47  (0.91-1.25) (0.91-1.28) (0.90-1.26) 
       
3: Initial BMD 1.21  1.15 1.04  0.01 0.06 0.66 (1.05-1.40) (0.99-1.34) (0.87-1.24) 
    Change in BMD 1.06  1.07 1.06  0.52 0.42 0.48 (0.90-1.24) (0.90-1.27) (0.90-1.26) 
       
*Per 1 SD (0.13 g/cm2) increase in BMD 
†Per 1 SD (1.42%) increase in BMD 
‡Adjusted for age (as time scale), clinic site, weight, vitamin D supplement use, estrogen therapy use, and 
family history of breast cancer 
§P value for trend 
**Overall p value  
Abbreviations used: BMD, bone mineral density; HR, hazard ratio; SD, standard deviation 
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 Table 18. Results of subgroup analyses to assess the association between BMD and risk 
of invasive breast cancer, Study of Osteoporotic Fractures 
 Invasive Breast Cancer 
 Age Adjusted Multivariable Adjusted† 
Cases / 
Non-
cases 
Cases / 
Non-
cases 
P 
value 
P 
value HR (95%CI) Initial BMD* HR (95%CI) 
       
Age      0.76‡ 
<75 years 111/2139 1.59 (1.05-2.39) 0.03 103/1972 1.49 (0.94-2.36) 0.09 
≥75 years 113/2980 1.51 (1.04-2.19) 0.03 107/2797 1.05 (0.69-1.59) 0.83 
       
BMI      0.60‡ 
<30 171/4204 160/3891 1.28 (0.91-1.79) 1.53 (1.13-2.08) 0.007 0.15 
≥30 53/915 50/878 1.13 (0.58-2.21) 0.73 0.97 (0.48-1.96) 0.93 
       
ET      0.97‡ 
Not current 172/4223 165/4012 1.51 (1.11-2.06) 0.009 1.30 (0.92-1.82) 0.14 
Current 46/802 45/757 1.50 (0.76-2.96) 0.24 1.13 (0.55-2.32) 0.73 
       
Family History      0.01‡ 
Negative 183/4330   172/4153   
Low BMD   0.77 (0.57-1.04) 0.09 0.94 (0.67-1.31) 0.69 
High BMD   1.30 (0.96-1.75) 0.09 1.07 (0.77-1.50) 0.69 
Positive 38/640 38/616     
Low BMD   0.28 (0.12-0.65) 0.003 0.34 (0.14-0.80) 0.01 
High BMD   3.52 (1.53-8.11) 0.003 2.99 (1.25-7.12) 0.01 
       
*Hazard ratios comparing BMD dichotomized at median (0.751) 
†Adjusted for age (as time scale), clinic site, weight, vitamin D supplement use, estrogen therapy 
use, and family history of breast cancer 
‡P value for interaction between subgroup variable and BMD 
 Abbreviations used: BMD, bone mineral density; HR, hazard ratio; SD, standard deviation 
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 7.0  GENERAL DISCUSSION 
Osteoporosis and breast cancer are two diseases that predominantly affect postmenopausal 
women. Osteoporosis, characterized by low bone mass, is the most common bone disease and 
a leading cause of fractures among the aging.14  Among women over age 50 in the United 
States, the prevalence of osteoporosis is between 13 and 18 percent.241  Breast cancer is the 
most commonly diagnosed cancer, and the second leading cause of cancer mortality among 
women in the United States.1  During 2008 alone, more than 182,000 new cases of invasive 
breast cancer and approximately 40,500 deaths were expected to occur.2   
Notwithstanding their different pathophysiologies, breast cancer and osteoporosis share 
several etiologic factors including estrogen. Estrogen is thought to play a central role in the 
development of breast cancer, due to its ability to stimulate proliferation of breast tissue,175 and 
osteoporosis, as evidenced by the rapid decrease in bone density following menopause.244  As 
the number of women with low bone mass increases with age (approximately 30% over age 50 
and more than 50% over age 80),245 so does the incidence of osteoporosis. However, the 
incidence of breast cancer also continues to increase with age, peaking at 75-79 years,6  
despite the dramatic drop in endogenous estrogen levels at menopause.  
The mechanisms by which breast cancer develops are not well understood, thus limiting 
opportunities for disease prevention. Therefore, it is extremely important to pursue research 
focused on breast cancer etiology. Only through the identification of modifiable factors 
associated with this disease can effective breast cancer prevention be realized. We undertook 
investigations of two factors of potential etiologic importance to breast cancer: vitamin D level 
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 and endogenous estrogen exposure. We sought to examine the association between three 
physiologic measures related to bone metabolism and calcium homeostasis, vitamin D, 
fractional calcium absorption, and bone mineral density, and breast cancer risk.  
7.1 ARTICLE 1: SERUM 25-HYDROXYVITAMIN D AND RISK OF ER+ BREAST CANCER 
IN POSTMENOPAUSAL WOMEN 
We used a case-cohort design to study the association between serum 25(OH)D and ER+ 
breast cancer in 502 women within the Study of Osteoporotic Fractures (SOF). 25(OH)D was 
measured using serum specimens collected at baseline. Low 25(OH)D was not associated with 
an increased risk of ER+ breast cancer overall. However, a protective effect was noted with 
lower 25(OH)D levels among women over 75 years of age.   
 The results of our prospective analysis are in agreement with a previous study which 
demonstrated no association among postmenopausal women.130  Two other studies reported an 
inverse association.131, 132  However, the comparability of our results with these later studies are 
limited due to methodological differences. A reduced tissue response to vitamin D with greater 
age is possible. Our observed association may be reflective of either a decline in the interaction 
between 1,25(OH)2D and VDRs in breast tissue, or diminished VDR expression with old age. 
Alternatively, tumors may develop mechanisms to negate anti-proliferative effects of 1,25(OH)2D 
at the cellular level.226 The positive association of a 50% reduction in risk among women 75 
years and older has not been reported previously and may indicate a change in the interaction 
between vitamin D and breast tissue.  
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 7.2 ARTICLE 2: RISK OF BREAST CANCER USING FRACTIONAL CALCIUM 
ABSORPTION AS A MARKER OF VITAMIN D RESISTANCE 
In this prospective study, we examined the association of between fractional calcium absorption, 
utilized as a marker tissue resistance to vitamin D, and breast cancer risk in SOF.  
Epidemiologic evidence suggests that vitamin D may reduce the incidence of breast cancer. 
However, reports in the literature have been inconsistent, particularly in regard to 
postmenopausal women. The possibility that age related tissue resistance to 1,25(OH)2D, the 
active vitamin D metabolite, may interrupt the protective mechanism by which vitamin D is 
thought to prevent breast cancer has not been investigated previously.  
Contrary to our hypothesis, we found a modestly significant increased risk of invasive 
breast cancer with increasing FCA. A stronger positive association was obtained among women 
over age 75 and those with low dietary calcium intakes (≤ 525 mg/d). Both calcium and vitamin 
D are thought to prevent breast cancer development through similar but independent effects on 
cell proliferation and differentiation.105, 233, 234, 236  The rate of FCA is inversely proportional to 
calcium intake and is also regulated by 1,25(OH)2D and potentially estrogen.160, 162, 163, 239 
Estrogen may interfere with the effect of calcium and vitamin D on cancer prevention by 
increasing intestinal calbindin D expression independent of vitamin D.232  Calbindin D is a 
cytosolic protein and the rate-limiting molecule in vitamin D-induced intestinal calcium 
transport.240  Increased calbindin D expression would lead to decreased circulating calcium 
levels, limiting calcium and vitamin D dependent apoptosis, and activate osteoblast formation 
resulting in increased calcium mineralization in bone and reduced bioavailability of systemic 
calcium.232  We did not find an interaction with estrogen therapy use, however small numbers 
may have been prohibitive.  
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 7.3 ARTICLE 3: LONG-TERM PREDICTION OF BREAST CANCER RISK IN 
POSTMENOPAUSAL WOMEN BY BONE MINERAL DENSITY 
In this prospective study, we investigated the association between BMD and the development of 
breast cancer over an average of 9.5 years in SOF. Overall a continuous BMD measure was not 
associated with breast cancer risk after adjusting for known breast cancer risk factors. We found 
a significantly increased risk of invasive breast cancer with total hip T-score measures in the 
normal (≥ -1.0) and low (-1.0 to -2.5) ranges compared to osteoporotic (≤ -2.5) based on WHO 
criteria. Furthermore, there was no improvement in the overall predictive value in a second 
measure of BMD, obtained over a mean 3.5 years later, in the determination of breast cancer 
risk. However, having a positive family history of breast cancer was associated with a significant 
3-fold increase in breast cancer risk among women with high compared to low BMD. 
The lack of an overall association, indicates that BMD may be a stronger predictor of 
early opposed to later breast cancer risk. Our results are consistent with a small study of peri-
menopausal women which also found no association between change in BMD and breast 
cancer risk.204  The significant interaction with family history of breast cancer is in-line with 
previous reports.190, 195  These women may be more sensitive to cumulative estrogen exposure 
as reflected in their BMD measurements. Genetic differences in estrogen synthesis, 
metabolism, and enzymes involved could enhance the bioavailability and/or biologic activity of 
steroid hormones such as estrogen.243 
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7.4 SUMMARY & FUTURE DIRECTIONS 
These research studies explored the association between vitamin D level and estrogen, two 
potentially etiologic factors for breast cancer. Our findings do not support a protective effect of 
25(OH)D level on ER+ breast cancer risk in postmenopausal women 65 years of age and older. 
The positive association among women 75 years and greater is suggestive of a change in the 
interaction of vitamin D in the breast; confirmation of this association in other populations is 
needed. Further investigations of the role of vitamin D on breast cancer development among 
elderly women are warranted. In particular, it will be important to better define the factors 
influencing 25(OH)D levels in this vulnerable age group. An important next step will be to 
measure localized levels of 1,25(OH)2D and 25(OH)D in both healthy and malignant breast 
tissues and to compare them as the correlations between these two metabolites are currently 
unknown. Future studies should also include adequate numbers of women with ER- breast 
cancer.  
We are the first to investigate the association between FCA and breast cancer risk. Our 
results suggest that high FCA, particularly among those with a low dietary calcium intake, is 
associated with an increased risk of postmenopausal breast cancer. More research is needed to 
fully understand the association between FCA and breast cancer risk. Accounting for other 
physiological measures such as sex steroid hormone levels, calcium, 1,25(OH)2D, 25(OH)D, 
and PTH in multivariable models may be useful. Correlates of FCA, including calcium, vitamin 
D, and estrogen have been investigated individually as etiologic factors for breast cancer. 
However, with the exception of estrogen, the reported associations have been inconsistent. 
Further investigations into the role of estrogen in conjunction with calcium and vitamin D levels 
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 on FCA may help to clarify their interdependence. Additionally, replication of these findings in 
other populations will be important.  
BMD was not found to be a significant long-term predictor of breast cancer risk after 
multivariable adjustment. Furthermore, a repeat BMD measure does not appreciably enhance 
the predictive value. However, our results do indicate that the association between bone mineral 
density and invasive breast cancer is modified by family history of breast cancer. Women with a 
positive family history coupled with high BMD are at increased risk. The extent to which BMD 
can be used to further elucidate the risk of postmenopausal breast cancer among women 
already at higher risk due to a positive family history should be studied. Identifying women at 
elevated risk is a critical step towards breast cancer risk reduction. Moreover, the research in 
these areas has not addressed the association among other racial groups, in particular those 
with darker skin pigmentation for whom inadequate circulating vitamin D levels are more 
prevalent and baseline BMD measurements are higher on average.  
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 8.0  PUBLIC HEALTH SIGNIFICANCE 
The public health burden of breast cancer and osteoporosis is substantial. These two diseases 
predominantly affect postmenopausal women, and due to our rapidly aging population, their 
impact is expected to worsen. While primary prevention of both these diseases is a desirable 
and sought-after goal, shared risk factors in opposing directions complicates such efforts. For 
instance, estrogen is thought to play a central role in the development of breast cancer, due to 
its ability to stimulate proliferation of breast tissue,175 and osteoporosis, as evidenced by the 
rapid decrease in bone density following menopause.244   Increased understanding of the 
etiologic factors and their underlying mechanisms are needed in order to identify potentially 
modifiable risk factors along with the women who might benefit from targeted prevention 
strategies. Established risk factors explain little of the variability in breast cancer and therefore 
there is a need to identify additional risk factors. This becomes an increasingly difficult task 
given the heterogeneity of breast cancer risk factors that exists between premenopausal and 
postmenopausal women, as well as the differences in pathologic features of breast tumors in 
older women. We therefore focused on how vitamin D, fractional calcium absorption, and bone 
mineral density relate to breast cancer risk.  
More than 50% of women over age 60 are reported to have inadequate summer serum 
25(OH)D levels,209 however the association with breast cancer risk has been understudied. Our 
investigation of the association between 25(OH)D and ER+ breast cancer adds to the small 
body of epidemiologic evidence. It is not known yet whether FCA rates will be useful in 
distinguishing between women with an increased breast cancer risk, however, our findings may 
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 help to clarify the inconsistent associations seen with studies of calcium and vitamin D to date. 
Finally, we have demonstrated a significant interaction in the relationship between bone mineral 
density and breast cancer by family history. Approximately 30% of women over age 50 have low 
bone mass as do more than 50% of women over age 80,245 potentially indicating that they have 
a reduced breast cancer risk. While routine screening can result in earlier detection of breast 
carcinomas, less invasive treatment options, better outcomes, and increased survival, screening 
recommendations for older women are severely lacking. The ability to better pinpoint a woman’s 
risk of postmenopausal breast cancer will allow for the establishment of solid screening 
guidelines.  
Through our investigations of these potentially etiologic factors and their association with 
breast cancer development, we have enhanced our knowledge regarding the interdependence 
of vitamin D, calcium, and estrogen. These results, along with those of future studies expanding 
upon our findings, may lead to improved opportunities for prevention and early detection of 
breast cancer. 
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 APPENDIX A 
SERUM 25-HYDROXYVITAMIN D AND RISK OF ER+ BREAST CANCER IN 
POSTMENOPAUSAL WOMEN 
A.1 CASE-COHORT SELECTION 
 
Figure 8. Case-cohort participant selection, Study of Osteoporotic Fractures 
The subcohort includes all individuals from the original subcohort (a random sample of the entire 
cohort, represented by a dashed - - - outline) with available serum. Fifteen cases were selected into 
the subcohort. The case group includes all incident ER+ breast cancer cases from the original case 
group (all ER+ cases diagnosed through 2000, represented by a dotted . . . outline) with available 
serum.  
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 A.2 ASSAY RELIABILTY SUBSTUDY 
 
 
 
Figure 9. Diasorin RIA 25(OH)D assay reliability, Study of Osteoporotic Fractures 
Masked duplicate serum 25(OH)D samples (n=25).  
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 A.3 KERNEL DENSITY PLOT OF 25(OH)D BY CASE COHORT STATUS 
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Figure 10. Kernel density plots of serum 25(OH)D by case-cohort status 
Breast cancer cases (n=156), subcohort cases (n=14), and subcohort non-cases (n=332). 
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Figure 11. Kernel density plots of log transformed serum 25(OH)D by case-cohort status 
Breast cancer cases (n=156), subcohort cases (n=14), and subcohort non-cases (n=332). 
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 A.4 LOWESS SMOOTHER OF 25(OH)D BY AGE AND CASE COHORT STATUS 
0
15
30
45
60
75
90
105
0
15
30
45
60
75
90
105
0
15
30
45
60
75
90
105
60 65 70 75 80 85 90
Breast Cancer Cases
Subcohort Cases
Subcohort Non-Cases
25(OH)D ng/ml Lowess: 25(OH)D ng/ml
25
(O
H
)D
 n
g/
m
l
Age at Baseline
Lowess smoother
 
Figure 12. Serum 25(OH)D distribution by age at baseline and case-cohort status 
Breast cancer cases (n=156), subcohort cases (n=14), and subcohort non-cases (n=332). 
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Figure 13. Serum log(25(OH)D) distribution by age at baseline and case-cohort status 
Breast cancer cases (n=156), subcohort cases (n=14), subcohort non-cases (n=332). 
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A.5 LOG 25(OH)D BY AGE, SEASON, SUPPLEMENT USE, BMI AND DISEASE STATUS 
Table 19. Median serum log (25(OH)D) by disease status and important study characteristics, 
Study of Osteoporotic Fractures 
 Log Transformed 25(OH)D  
 Median (IQR) p-value 
    
   Group 
Cases, n=170  3.31 3.1-3.5 0.51† Subcohort Non-Cases, n=332 3.31 3.1-3.5 
    
Age*    
65-69, n=147 3.33 3.2-3.5 
70-74, n=105 3.30 3.1-3.5 0.69‡ 75-79, n=58 3.28 3.1-3.5 
80+, n=22 3.39 3.0-3.5 
    
Season*    
Winter, n=64  3.28 3.0-3.6 
Spring, n=79  3.25 3.1-3.4 0.06‡ Summer, n=106 3.36 3.2-3.5 
Fall, n=83 3.32 3.1-3.5 
    
Vitamin D Supplement Use*    
Current, n=144 3.44 3.3-3.6 <0.01‡ Past, n=35 3.14 3.0-3.5 
Never, n=147 3.20 3.0-3.4  
    
BMI*, kg/m2    
< 25, n=164 3.35 3.2-3.6  
0.03‡ 25-29, n=112 3.26 3.1-3.5 
> 30, n=42 3.33 3.1-3.5  
    
*Comparison is among non-cases only 
†Wilcoxon two-sample rank-sum test 
‡Kruskal-Wallis test 
Abbreviations used: IQR, interquartile range 
 
 127 
 A.6 COVARIANCE MATRIX OF POTENTIAL MODEL COVARIATES 
25(OH)D
(ng/ml)
Age at
Baseline
Weight
(kg)
Distal
Radius
BMD
(gm/cm2)
Total
Estradiol
(pg/ml)
0 50 100
60
70
80
90
60 70 80 90
50
100
150
50 100 150
.2
.4
.6
.2 .4 .6
0
50
100
- 0.08 - 0.06 
(0.28) 
- 0.15 0.13 
(0.17) (<0.01) (0.02) 
- 0.13 - 0.14 0.03 
(0.02) (0.01) (0.62) 
0.26 0.23 
(<0.01) (<0.01) 
0.15 
(<0.01) 
 
 
Figure 14. Covariance matrix of continuous model covariates 
Spearman rank correlation: rho (p-value). 
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 APPENDIX B 
RISK OF BREAST CANCER USING FRACTIONAL CALCIUM ABSORPTION AS A MARKER 
OF VITAMIN D RESISTANCE  
B.1 LOWESS SMOOTHER OF FCA AND AGE BY DISEASE STATUS 
 
0
.2
.4
.6
.8
70 80 90 100 70 80 90 100
Non-Cases Cases
Lowess smoother
Fr
ac
tio
na
l C
al
ci
um
 A
bs
or
pt
io
n
Age (years)
 
Figure 15. Fractional calcium absorption distribution by age and disease status 
FCA measure at study baseline (SOF clinic visit 4). Breast cancer cases (n=257), non-cases 
(n=4778). 
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 B.2 KERNEL DENSITY OF FCA BY CALCIUM INTAKE AND DISEASE STATUS 
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
mean=0.361
Quartile 4
Non-Cases
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
mean=0.387
Quartile 4
Cases
  
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
mean=0.374
Quartile 3
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
mean=0.373
Quartile 3
  
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
mean=0.402
Quartile 2
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
mean=0.381
Quartile 2
  
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
Fractional Calcium Absorption
Kernel density estimate
Normal density
mean=0.413
Quartile 1
0
1
2
3
4
5
6
D
en
si
ty
0 .2 .4 .6 .8
Fractional Calcium Absorption
Kernel density estimate
Normal density
mean=0.389
Quartile 1
     
Figure 16. Kernel density plots of FCA distribution for cases and non-cases by quartile of 
calcium intake 
Calcium quartile cutpoints: 25%=455, 50%=775, 75%=1321. 
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 B.3 KAPLAN-MEIER SURVIVAL CURVE 
 
Figure 17. Kaplan-Meier survival curve of time to breast cancer diagnosis by FCA quartile 
Plogrank = 0.30. Follow-up in days from study baseline (i.e. clinic visit 4).  
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 B.4 CUBIC SPLINE OF FCA 
 
 
Figure 18. Cubic spline transformation of fractional calcium absorption 
Knot placement indicated by horizontal lines at quartile cutpoints (0.31420, 0.37175, 0.43370). Outer 
bands represent 95% confidence intervals. Plinearity=0.67. 
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 APPENDIX C 
LONG-TERM PREDICTION OF BREAST CANCER RISK IN POSTMENOPAUSAL WOMEN 
BY BONE MINERAL DENSITY  
C.1 CUBIC SPLINES OF BMD 
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Figure 19. Cubic spline transformation of bone mineral density 
Knot placement indicated by horizontal lines at quintile cutpoints (0.648, 0.721, 0.782, 0.860). Outer 
bands represent 95% confidence intervals. Plinearity=0.11. 
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Figure 20. Cubic spline transformation of bone mineral density among women with a negative 
family history of breast cancer 
Knot placement indicated by horizontal lines at quintile cutpoints (0.648, 0.721, 0.782, 0.860). Outer 
bands represent 95% confidence intervals. Plinearity=0.20. 
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Figure 21. Cubic spline transformation of bone mineral density among women with a positive 
family history of breast cancer 
Knot placement indicated by horizontal lines at quintile cutpoints (0.648, 0.721, 0.782, 0.860). Outer 
bands represent 95% confidence intervals. Plinearity=0.17. 
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